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Abstract 
 
Hereditary hemolytic anemias (HHAs) embrace a highly heterogeneous group 
of chronic disorders with a highly variable clinical picture. HHA encompass 
(1) hyporegenerative anemias (HAs), as congenital dyserythropoietic anemias 
(CDAs); (2) hemolytic anemias due to red cell membrane defects (HAMDs), as 
hereditary spherocytosis (HS) and hereditary stomatocytosis (HST). Although 
the workflow to diagnose these conditions is a normal clinical practice, 
differential diagnosis, classification, and patient stratification among HHAs are 
often very difficult. Beyond achieving a definitive diagnosis, knowing the 
genetic basis of these patients can be valuable also for guiding treatment. Next 
generation sequencing (NGS) refers to non-Sanger-based high-throughput 
DNA sequencing technologies. This technology plays a major role either in 
disease gene discovery or in clinical use for establishing a genetic diagnosis. 
Particularly, the major current application of NGS in diagnostics is through 
design of disease specific panel, named targeted (t)-NGS, in which a selected 
fraction of genes is sequenced. 
The primary aim of our study was the development of a fast, accurate, reliable 
and cost effective diagnostic/prognostic tool for HHAs based on t-NGS. In 
order to assess the reliability of this approach we created a t-NGS gene panel, 
named RedPlex, composed by 34 loci causative or candidates of HHAs. In 
silico design was performed by Agilent SureDesign web tool. For each locus, 
all coding regions, 5’ and 3’UTRs, and 100 bp flanking splice junctions were 
included. Sequence length was set at 150×2 nucleotides, and the predicted 
target size amounted to 538 regions (239.764 kb). Targeted enrichment was 
performed on 32 patients from 27 unrelated families by HaloPlex Target 
Enrichment System. High-throughput sequencing was performed by Illumina 
NextSeq 500. SureCall software was used for bioinformatic and computational 
analyses. RedPlex panel showed high sensitivity and specificity. It was able to 
capture at least 99.4% of 538 target regions with high and uniform coverage. 
We were able to obtain a conclusive diagnosis in approximately 72% of cases. 
In addition, a lot of patients (39%) showed multiple disease-associated variants 
suggesting complex inheritance. Indeed, t-NGS approach also allows the 
identification of “polygenic” genotypes, which may account for the phenotypic 
variability among HHA patients. Thus, the secondary aim of this project was 
the study of the interaction between mutated genes in HHA patients. We 
particularly focused on the functional interaction between two CDA-related 
genes, GATA1 and SEC23B. The demonstration of the direct interaction of 
GATA1 transcription factor on the SEC23B promoter provided also an 
explanation of the variability of phenotypes GATA1-related by means of the 
crosstalk of this gene with its target SEC23B. 
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1. Background 
 
Hereditary hemolytic anemias (HHAs) embrace a highly heterogeneous 
group of disorders characterized by hemolytic anemia of variable degree and 
by complex and often unexplained genotype-phenotype correlations. HHA are 
genetic disorders caused by mutations in more than 30 genes controlling red 
blood cell (RBC) production and structure. Mutations in these genes can lead 
to alterations in hemoglobin (Hb) levels, RBC differentiation and proliferation, 
cell membrane structure, defective activity of erythrocyte enzymes. This large 
group of pathologies comprises hemoglobinopathies, thalassemias, 
hyporegenerative anemias (HAs), hemolytic anemias due to red cell membrane 
defects (HAMDs). We will focus on (1) HAs, as congenital dyserythropoietic 
anemias (CDAs), (2) HAMDs, as hereditary spherocytosis (HS) and hereditary 
stomatocytosis (HST). 
 
1.1 Classification, diagnostic criteria and epidemiology of CDAs 
The term dyserythropoiesis refers to a condition of abnormal 
erythropoiesis affecting the differentiation and proliferation pathways of the 
erythroid lineage with a consequent defective production of RBCs (Iolascon et 
al. 2011). Dyserythropoietic anemias can be divided into primary and 
secondary forms, and both inherited and acquired types can occur. Among 
these different conditions, the CDAs are hereditary diseases that embrace a 
highly heterogeneous set of rare or very rare anemias that result from various 
kinds of abnormalities during late stages of erythropoiesis. They are counted as 
subtypes of inherited bone marrow failure syndromes (IBMFS), characterized 
by morphological abnormalities of erythroblasts in the bone marrow (BM) and 
ineffective erythropoiesis as predominant mechanism of anemia, accompanied 
by a hemolytic component (Iolascon et al. 2013). 
CDAs can be suspected in the presence of anemia and hemolytic signs, 
accompanied with reticulocytosis inadequate to the degree of anemia. In 
particular, the following criteria are required: (1) evidence of anemia, jaundice, 
splenomegaly; (2) evidence of ineffective erythropoiesis; (3) occurrence of 
typical morphological features of erythroblasts at BM examination; and (4) 
exclusion of other congenital anemias that fulfill criteria 1 and 2, such as 
thalassemia syndromes and other IBMFS (Gambale et al. 2016). The BM of 
CDA patients is always hypercellular, due to an exclusive and pronounced 
increase of erythroblasts, with erythropoietic/granulopoietic ratio (E:G) of 4 to 
10 (normal reference values 0.3 - 1.0). The expansion of the erythropoietic 
tissue leads to elevated serum concentration of the soluble transferrin receptor 
(sTfR), if iron deficiency is excluded. Dyserythropoiesis appears to be a 
morphological feature common to several conditions, and this could account 
for the difficulties in diagnosis of CDAs. However, the specific morphological 
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alterations of the erythroid precursors justify the heterogeneity of these 
disorders. Indeed, the three classical types of CDAs (types I, II and III) are 
defined on the basis of BM morphology (Iolascon et al. 2013). Inclusions of 
additional CDAs, the so called CDA variants, despite remarkable 
morphological studies, gradually led to overlapping entities and imposed a 
limitation on classification. In spite of these difficulties, morphological 
classification is still widely used in clinical practice (Table 1-1).  
 
Table 1-1. Morphological classification of CDAs 
Disease 
symbol 
Phenotype 
Bone marrow biopsy 
Optical microscopy Electron microscopy 
CDA I 
Congenital dyserythropoietic 
anemia type I 
Binucleated erythroblasts (3-
7%); thin chromatin bridges 
between nuclei of 
erythroblasts 
“Swiss cheese appearance” of 
the erythroblasts 
heterochromatin 
CDA II 
Congenital dyserythropoietic 
anemia type II 
Binucleated (10-30%); rare 
multinucleate erythroblasts 
Double plasma membrane of 
the erythroblasts 
CDA III 
Congenital dyserythropoietic 
anemia type III 
Giant multinucleate (up to 12 
nuclei) erythroblasts 
Clefts within heterochromatin, 
autophagic vacuoles, iron-
laden mitochondria, myelin 
figures in the cytoplasm 
CDA IV 
Congenital dyserythropoietic 
anemia type IV 
Tri- and multi-nucleate 
erythroblasts 
Invagination of nuclear 
membrane, intra-nuclear 
precipitated and nuclear 
blebbing 
XLTDA 
Thrombocytopenia X-linked 
with or without 
dyserythropoietic anemia 
Erythroblasts: megaloblastic 
features, nuclear irregularities, 
bi- and multi-nucleation 
Megakaryocytes: Small, 
dysplastic with signs of 
incomplete maturation 
Reduced numbers of platelet 
alpha granules and dysplastic 
features in megakaryocytes 
and platelets 
 
Nevertheless, the identification of the causative genes of the most common 
forms among CDAs in the last two decades represented an evident advantage 
for reclassifying these disorders, as well as in understanding their pathogenesis. 
Moreover, uncovering the molecular basis of CDAs helped to unravel novel 
aspects of the molecular biology of erythropoiesis. From the genetic 
standpoint, six different types of CDAs are included in the Online Mendelian 
Inheritance in Man (OMIM) compendium of human genes and genetic 
phenotypes so far (Table 1-2). However, this list is bound to extend. Indeed, 
the discovery of new causative genes is a continuous evolving process thanks 
to the development of high-throughput technologies, such as next generation 
sequencing (NGS). The identification of genetic variations underlying 
hereditary disorders marked the opening of a new era for genetic and clinical 
research. Indeed, beyond, obtaining definitive diagnosis and planning patient 
management, knowledge of the genetic basis of these disorders is crucial in 
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estimating their prevalence and geographical distribution (Gambale et al. 
2016). 
 
Table 1-2. Classification of CDAs by OMIM database 
Disease 
symbol 
Phenotype 
Phenotype  
MIM number 
Gene 
location 
Inheritance 
N 
cases
§
 
CDA Ia 
Congenital dyserythropoietic 
anemia type Ia 
224120 
CDAN1 
15q15.2 
AR < 100 
CDA Ib 
Congenital dyserythropoietic 
anemia type Ib 
615631 
C15orf41    
15q14 
AR < 10 
CDA II 
Congenital dyserythropoietic 
anemia type II 
224100 
SEC23B 
20p11.23 
AR > 200 
CDA III 
Congenital dyserythropoietic 
anemia type III 
105600 
KIF23 
15q21 
AD < 20 
CDA IV 
Congenital dyserythropoietic 
anemia type IV 
613673 
KLF1 
19p13.2 
AD < 10 
XLTDA 
Thrombocytopenia X-linked with 
or without dyserythropoietic 
anemia 
300367 
GATA1 
Xp11.23 
XLR < 10 
§ 
Number of cases with positive molecular analysis 
AD, Autosomal dominant; AR, Autosomal recessive; XLR, X-linked recessive 
 
In the majority of CDAs, inheritance is autosomal recessive, and due to the 
small number of offspring in most European families, single cases in one 
family are the rule rather than the exception. Together with the rarity of the 
disorder and the need to obtain bone marrow specimens for diagnosis, this 
explains why correct diagnosis is often delayed (Heimpel and Iolascon 2009), 
particularly in mild cases, even when anemia and/or hyperbilirubinemia have 
been evident for many years (Figure 1-1). 
 
 
Figure 1-1. Age at diagnosis in CDA I and CDA II and onset age in CDA II. CDA I and II 
are the most common types among CDAs. Adapted from Heimpel and Iolascon 2009. 
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According to the estimation by Heimpel and colleagues in 2010, the prevalence 
of CDAs varies widely among European regions, with minimal values of 0.04 
cases/million in North Europe and the highest in Mediterranean countries, 
particularly in Italy (2.49/million). This is mainly true for CDA II, which is 
more frequent than CDA I with an overall ratio of approximately 3.0 (Heimpel 
et al. 2010b). The studies on molecular epidemiology of CDA I and II 
highlighted the elevated allelic heterogeneity of both conditions as most of the 
causative variations are inherited as private mutations (Iolascon et al. 2012). 
However, recurrent mutations have been found in both CDA I and CDA II 
patients. In particular, the Arg1042Trp mutation in the CDA I causative gene 
CDAN1 is a founder mutation in the Bedouin population (Tamary et al. 2008), 
whereas the amino acid substitutions Glu109Lys and Arg14Trp in the CDA II 
causative gene SEC23B show the highest frequency in Mediterranean area 
(Morocco, Israel and Italy), where a founder effect for both variants has been 
described (Russo et al. 2011) (Figure 1-2). 
 
 
Figure 1-2. Molecular geocode of SEC23B alleles in Europe. In white are represented the 
countries in which have been reported CDA II cases so far. Mutations found in more than three 
independent pedigrees were shown with different colors. For each variant the total number of 
alleles and the relative frequency were indicated. Private mutations (i.e., the mutations present 
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in less than 3 unrelated patients) were colored in gray. Pie charts show the number of alleles 
for each mutation. Dotted red line highlights the region in which a founder effect has been 
demonstrated. Adapted from Russo et al. 2014. 
 
However, molecular geocode of CDA II pathogenic alleles suggested the 
presence of multiple founder effects in different geographical areas of the 
world (Russo et al. 2014) (Figure 1-3). 
 
 
Figure 1-3. Molecular geocode of SEC23B alleles in the world. In white are represented the 
countries in which have been reported CDA II cases so far. Mutations found in more than three 
independent pedigrees were shown with different colors. For each variant the total number of 
alleles and the relative frequency were indicated. Private mutations (i.e., the mutations present 
in less than three unrelated patients) were colored in gray. Pie charts show the number of 
alleles for each mutation. Dotted red line highlights the region in which a founder effect has 
been suggested (Southeast Asia and Oceania). Adapted from Russo et al. 2014. 
 
The pathomechanisms of CDAs involve the regulation of both DNA replication 
and cell division. Particularly, CDA II, CDA III and probably CDA Ib could be 
due to deregulation of mechanisms involved in cell division. Indeed, SEC23B 
is a component of the midbody, an essential structure in the telophase; KIF23 
mutant causes the furrow regression, thus inhibiting the cytokinesis; C15orf41 
might encode a protein with homology to the Holliday junction resolvases, 
which are involved in chromosome segregation. Otherwise, the pathogenic 
mechanisms of transcription factor-related CDAs could be due to impairment 
of mechanisms involved in DNA synthesis and chromatin assembly. Indeed, 
during cell division, the transcription factors GATA1 and KLF1 could be 
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retained focally within mitotic chromatin to facilitate the rapid reactivation of 
the transcription of tissue-specific gens upon entry into G1 phase. Similarly, 
CDA Ia-Ib could be due to impaired mechanisms involved in chromatin 
assembly. Indeed, codanin-1 interacts with the cytosolic Asf1-H3-H4-importin-
4 complex, involved in nucleosome assembly and disassembly, while C15orf41 
interacts with Asf1b (Figure 1-4). 
 
 
Figure 1-4. Pathogenetic mechanisms of CDAs involve the regulation of DNA replication 
and cell division. (a) The pathogenic mechanisms of CDA II, CDA III and probably CDA Ib 
could be due to deregulation of mechanisms involved in cell division. (b) The pathogenic 
mechanisms of transcription factor-related CDAs, as well as of CDA Ia–Ib could be due to 
impairment of mechanisms involved in DNA synthesis and chromatin assembly. Adapted from 
Gambale et al. 2016. 
 
CDA type I  
Most of the CDA I patients exhibit lifelong macrocytic anemia with variable 
values of Hb and mean cell volume (MCV) ranging between 100 and 120 fL; 
however, it can be normocytic in childhood. Relative reticulocytopenia is 
typically observed accompanied to increased Hb turnover as attested by 
indirect hyperbilirubinemia, high lactate dehydrogenase (LDH) value and low 
or absent plasma haptoglobin. All patients develop splenomegaly in 
adolescence or adulthood, while about 20% of cases show congenital 
anomalies, particularly syndactyly in hands or feet, absence of nails or 
supernumerary toes, pigeon chest deformity and short stature (Iolascon et al. 
2012; Gambale et al. 2016). BM smear shows hypercellularity and erythroid 
hyperplasia (E:G of 4 and 8 times the normal). Approximately 30-60% of 
polychromatic erythroblasts show abnormalities of nuclear and chromatin 
structure. Indeed, the morphological pathognomonic feature of CDA I is the 
presence of thin chromatin bridges between the nuclei pairs of erythroblasts. A 
minority of erythroblasts shows bi- or multinuclearity, but in contrast to CDA 
II, the nuclei of binucleated cells are of different size and shape. At electron 
microscopy (EM), heterochromatin is denser than normal and forms 
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demarcated clumps with small translucent vacuoles, giving rise to the metaphor 
of “Swiss cheese appearance” (Heimpel et al. 2010a). CDA I is inherited in an 
autosomal-recessive manner. The first causative gene in which pathogenic 
variants were identified has been CDAN1 (chr15q15.2) (Dgany et al. 2002) that 
encodes a ubiquitously expressed protein, codanin-1 (Table 1-2). More than 
100 patients (CDA Ia) and 30 unique disease-causing mutations have been 
described so far. Codanin-1 is part of the cytosolic Asf1-H3-H4-importin-4 
complex, which is implicated in nucleosome assembly and disassembly (Figure 
1-4). Cdan1 knockout mice die in utero before the onset of erythropoiesis, 
suggesting a critical role of codanin-1 in developmental processes beyond 
erythropoiesis (Renella et al. 2011). Of note, no homozygous patients for null 
mutations have been described so far. Homozygous or compound heterozygous 
in CDAN1 gene cover approximately 50% of CDA I patients, while in 30% of 
cases only a single mutant allele can be identified. Recently, the second 
causative gene of CDA I has been identified. In particular, two different 
mutations in C15orf41 gene (chr 15q14) were found in three unrelated 
Pakistani families, classified as affected by CDA Ib (Table 1-2) (Babbs et al. 
2013). C15orf41 is predicted to encode a divalent metal ion-dependent 
restriction endonuclease, with a yet unknown function. In cultured 
erythroblasts, C15orf41 produces a spliced transcript encoding a protein with 
homology to the Holliday junction resolvases (Figure 1-4). However, it has 
been shown that C15orf41 interacts with Asf1b, supporting the hypothesis that 
the primary defect in CDA Ib is in DNA replication and chromatin assembly. 
CDA type II 
The main clinical finding to diagnose CDA II is the presence of normocytic 
anemia of variable degree, with normal or only slightly increased reticulocyte 
count, but not adequate to the degree of anemia (ineffective erythropoiesis); it 
is often accompanied with jaundice and splenomegaly due to the hemolytic 
component. As described in a recent survey on 205 patients, CDA II generally 
presents mild anemia (mean Hb 9.6 ± 0.2 g/dL), but a wide spectrum of clinical 
presentations can occur, from asymptomatic to severe (Hb range 3.6-16.4 
g/dL). Indeed, approximately 10% of cases result symptomless, whereas 20% 
of patients undergo a regimen of transfusion dependence (Russo et al. 2014). 
The term “congenital” could sound inappropriate in some cases since this 
disorder is often diagnosed during adulthood. Of note, the mean age of onset 
symptoms is approximately 3-4 years, but six patients were reported to have a 
prenatal onset. However, the age of diagnosis is delayed, 22.2 ± 1.7 years. This 
could be explained either by the occurrence of mild symptoms or by the 
misdiagnosis of CDA II with HS. Similarly to CDA I, the BM is hypercellular 
with distinct erythroid hyperplasia and subsequent increased E:G. The most 
specific finding of CDA II marrow is the presence of more than 10% mature 
binucleated erythroblasts with equal size of two nuclei. Upon EM examination, 
mature erythroblasts show discontinuous double membrane, which is due to the 
presence of vesicles loaded with proteins of endoplasmic reticulum (ER) that 
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appear to be running beneath the plasma membrane. Analysis of RBC 
membrane proteins by sodium dodecyl sulfate polyacrylamide (SDS-PAGE) 
gel electrophoresis reveals a narrower band size and faster migration of band 3 
in most of the CDA II patients (95%) (Figure 1-5). Thus, this biochemical 
feature represents a specific diagnostic hallmark of the disease. Moreover, the 
hypoglycosylation of band 3 has been associated to the occurrence of the 
hemolytic component observed in CDA II patients by means of increased 
clusterization of this protein on RBC surface, which in turn leads to IgG 
binding and phagocytosis of RBCs (De Franceschi et al. 1998).  
 
 
Figure 1-5. Morphological and biochemical features of CDA II erythroblasts. (a) CDA II 
bone marrow at light microscopy highlights erythroid hyperplasia with bi- or multinucleated 
late erythroid precursors. (b) CDA II bone marrow at EM highlights morphological 
abnormalities of CDA II erythroblasts. (c) Biochemical analysis of RBC membrane proteins 
from CDA II patient (lane 1) shows the typical hypoglycosylation of Band 3, with an increased 
anodic mobility on SDS-PAGE compared to healthy control (lane 2). 
 
Both morphological features of the BM and biochemical alterations of RBC 
membrane proteins can be explained by the mutations in the causative gene 
SEC23B (chr 20p11.23) (Table 1-2) (Schwarz et al. 2009). CDA II is an 
autosomal recessive disease that belongs to the group of cytoplasmic coat 
protein (COP) II-related human genetic disorders (Russo et al. 2013a). SEC23B 
gene encodes the homonymous member of COPII complex, which is involved 
in the secretory pathway of eukaryotic cells. This multi-subunit complex 
mediates anterograde transport of correctly folded cargo from the ER toward 
the Golgi apparatus. Most of the cases (86%) show biallelic mutations in the 
SEC23B gene, although a subset of patients with an incomplete pattern of 
inheritance (14.0%) has been identified. More than 80 different mutations in 
SEC23B have been described so far, even if recurrent variants have been also 
described (Figure 1-6).  
17 
 
 
 
Figure 1-6. SEC23B function and mutations. (a) Schematic representation of ER-Golgi 
transport. After translation, folded nascent proteins are exported from the ER in COPII 
anterograde transport vesicles. In mammalian cells, COPII vesicles generate a structure known 
as ER-Golgi intermediate compartment (ERGIC). The ERGIC is a site for concentrating 
retrograde cargo into COPI vesicles, which bud from pre-Golgi and Golgi compartments to 
recycle vesicle components and retrieve resident proteins that have escaped the ER. Adapted 
from Russo et al. 2013a. (b) Model for COPII vesicle assembly. In yeast, COPII-coated 
vesicles form by the sequential binding of Sar1-GTP, the inner complex proteins Sec23- Sec24 
and the outer complex components Sec13-Sec31 on ER. The transport of both integral 
membrane cargo and soluble secretory cargo is shown. Adapted from Russo et al. 2013a. (c) 
Localization of mutations in SEC23B gene. Exons and introns from a reference sequence 
(Ensembl transcript ID: ENST00000377475) are shown, distances to scale. Above the physical 
map, missense and splicing mutations are shown. Below the map, nonsense mutations (direct 
stop codons and frameshift mutations) and the only one in frame deletion are shown. The 
common mutations (found in at least two alleles) are shown in the boxes, whereas those that 
are sporadic (only one allele mutated) are represented by symbols, as indicated in the key. 
Adapted from Iolascon et al. 2011 
 
Despite the elevated number of described cases and identified mutations, the 
pathomechanism of CDA II is not yet well understood. Although no direct 
evidence exists, SEC23B could play an active role in assembly or 
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deconstruction of the midbody, where it was identified in a proteomic screen 
(Skop et al. 2004). The presence of SEC23B in this subcellular compartment 
could account for an explanation of the impaired cytokinesis observed in CDA 
II erythroblasts (Figure 1-4). Otherwise, the multinuclear phenotype could be 
secondary to the aberrant glycosylation of specific proteins required for cell 
division, leading to defects in this process. However, it remains to unravel how 
alterations in a ubiquitous gene can result in clinical manifestations restricted 
to the erythropoietic tissue. The specificity of the CDA II phenotype seems to 
be due to the tissue-specific expression of SEC23B during erythroid 
differentiation (Schwarz et al. 2009). Alternatively, it could be explained by the 
presence of erythroid-specific cargoes (such as band 3), which might require 
high levels and full function of a specific COPII component to be correctly 
transported (Russo et al. 2013a). The pathophysiology study is difficult mainly 
due to the absence of a reliable animal model. Different models of SEC23B-
deficient mice have been generated without reproducing CDA II phenotype. 
Indeed, SEC23B deficiency results in different phenotypes in humans and mice 
(Tao et al. 2012; Khoriaty et al. 2014). In particular, the absence of phenotype 
in SEC23B-deficient mice seems to be related to the different 
SEC23B/SEC23A expression ratio in murine and human tissues. Indeed, this 
ratio is higher in mouse pancreas compared to BM, whereas it is higher in 
human BM relative to pancreas. Of note, SEC23A and SEC23B are paralogous 
components of the COPII complex. This observation is in agreement with the 
compensatory expression of SEC23A that seems to ameliorate the effect of low 
SEC23B expression alleles in CDA II patients (Russo et al. 2013b). So far, the 
only reliable in vitro model for CDA II is the SEC23B-silencing in K562 cells, 
which recapitulates the cytokinesis defect, with a significant increase of 
percentage of binuclearity and an increased size of nuclei in SEC23B-silenced 
cells (Schwarz et al. 2009). 
CDA type III 
CDA III is the rarest form among classical CDAs. Patients show absent to 
moderate anemia with normal or slightly elevated MCV, and normal or faintly 
low relative number of reticulocytes. Twenty percent of patients received blood 
transfusions. Common symptoms are weakness, fatigue and headache; jaundice 
and biliary symptoms are also reported. Unlike from other CDAs, none of the 
described patients show enlarged liver or spleen. Hemolysis is also present as 
attested by low or absent haptoglobin and increased LDH. No significant 
changes in serum iron, transferrin or ferritin concentrations are observed. In 
some cases, serum electrophoresis analysis showed an M-component, IgG-k 
type: in particular, one patient with myeloma and four with monoclonal 
gammopathy were described. At optical microscopy, BM highlights erythroid 
hyperplasia, with the characteristic giant multinucleate erythroblasts; at EM, 
clefts within heterochromatin, autophagic vacuoles, iron-laden mitochondria 
and myelin figures in the cytoplasm were described. In 2013, the causative 
gene of this condition was identified by target sequencing: KIF23 gene (chr 
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15q21) encodes a kinesin-superfamily protein MKLP1 that is a component of 
centralspindlin, a subcellular structure required for proper formation of the 
central spindle and the midbody and thus essential for cytokinesis (Liljeholm et 
al. 2013). MKLP1 mutant affects the function of this protein during 
cytokinesis, leading to the formation of the large multinucleated erythroblasts 
found in BM of the patients (Table 1-2; Figure 1-4). 
Transcription factor-related CDAs 
CDA IV and X-linked thrombocytopenia with or without dyserythropoietic 
anemia (XLTDA) belong to this subgroup of CDAs (Figure 1-4). 
To date, four patients with CDA IV have been reported. All of them are 
characterized by the occurrence of normocytic anemia, generally severe, with 
Hb 5-9.5 g/dL. Conversely to classical CDAs, reticulocyte count is normal or 
slightly increased with respect to the degree of anemia; elevated values of HbF 
(>30%) are also observed (Arnaud et al. 2010; Jaffray et al. 2013). At BM, 
light microscopy erythroid hyperplasia, dyserythropoiesis signs, as basophilic 
stippling of polychromatic erythroblasts and erythrocyte, and internuclear 
bridging are observed. EM shows immature erythroid progenitors with atypical 
cytoplasmic inclusions, enlarged nuclear pores, invagination of nuclear 
membrane and marked heterochromatin. All four patients exhibit the same 
autosomal-dominant mutation (p.Glu325Lys), in heterozygous state, in KLF1 
gene (chr 19p13.2) (Table 1-2). KFL1 encodes the homonymous protein, which 
is an essential erythroid-specific transcription factor, member of the Krüppel-
like factor family. KLF1 is a well-known transcriptional activator in 
erythropoiesis, but it also exerts transcriptional repression in megakaryopoiesis. 
It plays a critical role in regulating the switch between fetal and adult Hb 
expression and is required in terminal erythroid differentiation for the cell-
cycle progression.  
XLTDA is a CDA variant characterized by anemia of variable degree, ranging 
from hydrops fetalis and transfusion-dependency to dyserythropoiesis without 
anemia, macro-thrombocytopenia with hypo-granulated platelets (PLT) and 
bleeding tendency. BM features are dyserythropoiesis, megakaryocytes 
decreased in number with cytoplasmic vacuoles and absence of platelet 
membrane demarcation. This is an X-linked recessive disease (Table 1-2), due 
to mutations in the X chromosomal gene GATA1 gene (chr Xp11.23), encoding 
for the zinc finger DNA binding protein GATA1. This latter belongs to the 
GATA family of transcription factors, involved in the regulation of 
hematopoiesis. In particular, GATA1 plays an essential role in the development 
and maintenance of both erythroid and megakaryocytic lineages. GATA1 has 
two zinc finger domains: the C-terminal is necessary for DNA binding, while 
the N-terminal mediates interaction with FOG1 (friend of GATA1), a cofactor 
of GATA1. Of note, the most likely pathogenic mechanism in these disorders 
involves the GATA1-FOG1 interaction. 
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The role of transcriptional regulator of different genes and pathways may 
explain how different mutations in the same gene can result in disparate 
phenotypes. Indeed, beyond CDA IV, KLF1 mutations have been associated to 
in(Lu)blood type and hereditary persistence of fetal hemoglobin. Similarly, 
there are different syndromic conditions related to GATA1 mutations, in which 
thrombocytopenia can be associated to thalassemia, congenital erythropoietic 
porphyria or Diamond–Blackfan anemia (DBA)-like disease. Moreover, the co-
inheritance of GATA1 and other CDA-gene mutations could explain the 
occurrence of more severe phenotypes (Di Pierro et al. 2015). 
 
1.2 Classification, diagnostic criteria and epidemiology of HAMDs 
Red cell membrane disorders are inherited diseases due to mutations in 
genes encoding for several membrane or cytoskeletal proteins of RBCs, 
resulting in decreased red cell deformability, reduced half-life and premature 
removal of the erythrocytes from bloodstream. Extensive studies on RBC 
membrane have allowed the comprehension of both structure and function of 
this subcellular compartment (Figure 1-7). Thus, the molecular bases of the 
overwhelming majority of cases of RBC membrane alteration have been 
completely defined. 
 
 
Figure 1-7. A simplified cross-section of the erythrocyte membrane. The RBC membrane is 
composed of integral membrane proteins incorporated into a phospholipid bilayer. The 
network of cytoskeletal proteins is anchored to the membrane via the transmembrane proteins. 
GPA, glycophorin A; Rh, Rhesus polypeptide; B-4.1, protein band 4.1; B-4.2, protein band 4.2; 
GPC, glycophorin C;  RhAG, Rh-associated glycoprotein. 
 
The red cell membrane disorders include both (i) structural defects and (ii) 
altered permeability of RBC membrane. The first subgroup comprises: HS, 
hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), Southeast 
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Asian ovalocytosis (SAO); the second one: dehydrated hereditary 
stomatocytosis (DHS), overhydrated hereditary stomatocytosis (OHS), familial 
pseudohyperkalemia (FP), and cryohydrocytosis (CHC) (Table 1-3).  
 
Table 1-3. Classification of HAMDs by OMIM database 
Disease 
symbol 
Phenotype 
Phenotype  
MIM number 
Gene Location Inheritance 
HS1 Hereditary spherocytosis type 1 182900 ANK1 8p11.21 AD 
HS2 Hereditary spherocytosis type 2 616649 SPTB 14q23.3 AD 
HS3 Hereditary spherocytosis type 3 270970 SPTA1 1q23.1 AR 
HS4 Hereditary spherocytosis type 4 612653 SLC4A1 17q21.31 AD 
HS5 Hereditary spherocytosis type 5 612690 EPB42 15q15.2 AR 
HE1 Hereditary elliptocytosis 1 611804 EPB41 1p35.3 AD 
HE2 Hereditary elliptocytosis 2 130600 SPTA1 1q23.1 AD 
HE3 Hereditary elliptocytosis 3 - SPTB 14q23.3 AD 
HPP Hereditary Pyropoikilocytosis 266140 SPTA1 1q23.1 AR 
SAO Ovalocytosis Southeast Asian type 166900 SLC4A1 17q21.31 AD 
OHS Overhydrated hereditary stomatocytosis 185000 RHAG 6p12.3 AD 
DHS1 
Dehydrated hereditary stomatocytosis 
with or without pseudohyperkalemia 
and/or perinatal edema 
194380 PIEZO1 16q24.3 AD 
DHS2 Dehydrated hereditary stomatocytosis 2 616689 KCNN4 19q13.31 AD 
FP Familial pseudohyperkalemia 2 609153 ABCB6 2q35-q36 AD 
CHC Cryohydrocytosis 185020 SLC4A1 17q21.31 AD 
AD, Autosomal dominant; AR, Autosomal recessive 
 
HAMDs due to RBC structural defects  
HS, also known as the Minkowski Chauffard disease, is the most common 
inherited red cell membrane disorder with an estimated prevalence of 1:2000-
5000 in the Caucasian population. However, this value is probably even higher, 
due to under-diagnosed moderate forms. HS refers to a group of heterogeneous 
inherited anemias showing a broad spectrum of clinical severity, ranging from 
asymptomatic condition to severe form, characterized by transfusion-dependent 
life-threatening anemia and rarely by hydrops fetalis or fetal death. The main 
clinical findings of HS are hemolytic anemia of variable degree, 
hyperbilirubinemia, jaundice, splenomegaly, cholelithiasis. Laboratory findings 
are heterogeneous too: increased reticulocyte count (range 6% - >10%, until to 
35% in severe cases); increased mean corpuscular Hb concentration (MCHC, ≥ 
34.5g/dl) in > 50% of patients; increased RBC distribution width (RDW, >14) 
in most of patients; increased number of spherical-shaped erythrocytes 
(spherocytes) in peripheral blood smear. The first tests for HS diagnosis are: 
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NaCl osmotic fragility (OF), on both fresh blood and blood incubated at 37°C 
after 24h), standard and acidified glycerol lysis test (AGLT), pink test and flow 
cytometric analysis of eosin-5-maleimide-labeled erythrocytes (EMA binding). 
Unfortunately, neither EMA binding nor OF testing are able to detect 100% of 
HS patients, especially mild HS, since OF has low sensitivity. The quantitation 
of major erythrocyte membrane proteins via SDS-PAGE allows the 
identification of different subsets of HS patients; however, some subjects 
remain unclassified by this technique. Finally, ektacytometry is a highly 
sensitive test of membrane deformability (Gallagher et al. 2013). The 
phenotype variability is linked to different molecular defects associated to 
extent of loss of membrane surface area relative to intracellular volume, which 
leads to spherically shaped erythrocytes with decreased deformability (Table 1-
3). The increased membrane fragility is caused by highly heterogeneous 
molecular defects due to deficiency and/or dysfunction in erythrocyte 
membrane proteins, particularly ankyrin (ANK1), α- and β-spectrin (SPTA and 
STPB), band 3 (SLC4A1), and protein 4.2 (EPB42) (Figure 1-7). 
Approximately 75% of HS cases exhibit an autosomal dominant pattern of 
inheritance, associated with mutations in ANK1, SPTB and SLC4A1 genes. In 
the remaining 25% of patients, autosomal recessive de novo mutations in SPTA 
and EPB42 genes were observed (Table 1-4). 
 
Table 1-4. Genetic and biochemical features of HS, HE and HPP 
Disease Inheritance Genes 
Biochemical features of RBC 
membrane proteins
§
 
HS 
75% AD 
25% de novo/AR 
ANK1 (50% of cases) 
SPTB (20% of cases) 
SPTA1 (rare) 
SLC4A1 (20% of cases) 
EPB42 (rare) 
-Mutations in ANK1: ↓ spectrin and band 4.2 
-Mutations in SPTB: ↓ spectrin 
-Mutations in SLC4A1: ↓ band 3 and 4.2 
-Mutations in EPB42: absence of band 4.2 
HE AD 
EPB41 (severe forms) 
SPTB  
SPTA1 
-Mutations in EPB41: absence of band 4.1 
and ↓ of glycophorin C and D 
-Mutations in SPTA1 and SPTB: ↑ 
dimer/tetramer ratio on non-denaturing gel 
HPP AR 
SPTA1 mutations associated 
with αLELY variant 
 
AD, Autosomal dominant; AR, Autosomal recessive 
§
Biochemical features at SDS-PAGE analysis 
 
HE belongs to a heterogeneous group of disorders characterized by the 
presence of elliptical-shaped erythrocytes (elliptocytes) at peripheral blood 
smear with variable clinical manifestations, from asymptomatic carrier state to 
severe, transfusion-dependent hemolytic anemia. The worldwide incidence of 
HE is 1:2000-4000 individuals, but it results higher in some African regions 
(1:100). A subtype of HE is HPP, a rare severe hemolytic anemia characterized 
by poikilocytosis, fragmented erythrocytes, resulting in low MCV (50-60 fL), 
microspherocytes. The patients show marked splenomegaly, and splenectomy 
is therefore usually recommended. There is a strong association between HE 
and HPP, with a third of family members of HPP patients exhibiting typical 
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HE. Moreover, many HPP patients suffer from severe hemolytic anemia in 
infancy that gradually improves, evolving toward typical HE during adulthood. 
The main defect in HE erythrocytes is mechanical weakness or fragility of the 
erythrocyte membrane skeleton due to defective horizontal connections of 
cytoskeletal proteins such as dimer-dimer interactions of spectrin and spectrin-
actin-protein 4.1 of the junctional complex (Figure 1-7). HE is inherited in an 
autosomal dominant pattern with rare cases of de novo mutations and the 
exception of recessive autosomal inheritance of HPP. HE can be due to 
mutations in EPB41, SPTA1 and SPTB genes that lead to serious damage in the 
association of spectrin dimers (Iolascon et al. 2003). The HE shows high inter- 
and intra-familial phenotypic variability, due to the modifier alleles. One 
example is the αLELY (Low Expression Lyon) in SPTA1 gene, a hypomorphic 
haplotype composed by two variants, the missense Leu1857Val and the 
splicing variant in the intron 45. This hypomorphic haplotype alone causes a 
minimum damage in both heterozygous and homozygous state since the 
spectrin α chains are produced in excess (3 to 4 fold compared to spectrin  
chain); otherwise, when it is associated with a HE mutation in SPTA1, the 
resulting phenotype is severe, i.e. the HPP (Table 1-4). 
SAO is a very common condition in the aboriginal peoples from Papua New 
Guinea, Indonesia, Malaysia, Philippines and southern Thailand, in areas 
where malaria is endemic, with prevalence varying between 5 and 25%. 
Indeed, this condition offers protection against all forms of malaria. Despite the 
reduced in vitro deformability of SAO erythrocytes, patients are asymptomatic 
and the diagnosis is made accidentally as a result of the examination of the 
peripheral blood smear, showing the characteristic rounded elliptocytes 
(ovalocytes). However, in newborns it can manifest as hemolytic anemia and 
may require phototherapy. SAO is inherited as an autosomal dominant trait and 
is caused by a deletion of 27 nucleotides in SLC4A1 leading to the loss of the 
amino acids 400-408 of band 3 protein. The deletion is in linkage 
disequilibrium with the Memphis polymorphism (p.Lys56Glu) in SLC4A1 
gene. SAO erythrocytes show a small loss of monovalent cations when 
exposed to low temperatures, with a reduction of anions flux. Thus, SAO could 
be classified as genetic disease affecting the permeability of RBC membrane. 
Despite the frequency of heterozygotes, homozygotes are not viable. Indeed, 
the homozygosity could create an alteration of the ion flux of RBCs and a 
severe distal renal acidosis due to the loss of band 3 (also expressed in the 
kidney), that could be lethal (Iolascon et al. 2003). 
HAMDs due to altered permeability of RBC membrane 
HST includes both DHS and OHS, which show alteration of the permeability 
of the RBC membrane to monovalent cations Na+ and K+ with consequent 
alteration of the intracellular cationic content and alterations of cell volume 
(Delaunay 2007). DHS is the most represented among the HST, with an 
incidence of approximately 1:50000 births. It is 10-20 times less frequent than 
HS, with which it can be, however, confused. The phenotype ranges from 
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asymptomatic forms to severe, with massive hemolysis. Generally, DHS 
patients show hemolytic well-compensated anemia, with high reticulocyte 
count and tendency to macrocytosis, mild jaundice. The main characteristic of 
RBCs is the cell dehydration, because of the loss of the cation content, with a 
consequent increase of MCHC (>36 g/dL). At blood smear the stomatocytes, 
erythrocytes with the characteristic central spot mouth-shaped, are quite rare, 
making diagnosis often difficult. In addition, it may be difficult when the 
clinical picture is associated with pseudohyperkalemia and/or perinatal edema, 
in the so-called form pleiotropic syndrome (Delaunay 2004). For these reasons, 
the condition may be overlooked for years or decades before reaching a 
conclusive diagnosis. DHS is inherited as an autosomal dominant trait. The 
candidate gene locus was firstly localized at 16q23-24 (Carella et al. 1998). 
Subsequently, PIEZO1 gene was identified as causative of both isolated and 
syndromic forms of DHS by exome sequencing (Zarychanski et al. 2012; 
Andolfo et al. 2013). PIEZO1 encodes a mechanoreceptor, an ion channel 
activated by pressure (Figure 1-7). This protein has been identified in the RBC 
membrane and in mice it has been shown to form a tetramer of about 1.2 
million daltons; it is therefore the largest ion channel identified to date. 
Recently, a novel DHS causative gene, KCNN4, has been identified in four 
different DHS2 families (Table 1-3). KCNN4 gene encodes the Gardos 
channel, a widely expressed Ca
2+
-dependent K
+
 channel of intermediate 
conductance that mediates the major K
+
 conductance of erythrocytes (Rapetti-
Mauss et al. 2015; Andolfo et al. 2015).  
OHS is a very rare subtype among HST, overall 20 cases reported worldwide. 
Contrary to DHS, RBCs are hydrated due to an increase, from 20 to 40 times, 
in the loss of cations (Stewart 2004). OHS is associated with more severe 
phenotypes compared to DHS. In addition to reticulocytosis, it is characterized 
by a sharp increase in MCV (> 110 fL) and decreased MCHC (24-30 g/dl). The 
number of stomatocytes is usually much higher than that observed in DHS. The 
causative gene of this condition is RHAG, encoding the Rh-associated 
glycoprotein (RhAG) which acts as an ammonia channel (Genetet et al. 2012) 
(Figure 1-7). The stomatin protein has been found at low or absent levels in 
OHS patients, but no mutations have been found in the encoding gene so far. 
FP and CHC are additional forms of stomatocytosis. FP is not associated with 
hemolytic anemia and stomatocytes are only rarely observable at peripheral 
smear. Conversely, CHC patients show hemolytic anemia of variable degree. 
RBCs from FP patients exhibit a loss of K
+
 at low temperatures (<37°C, mostly 
8-10°C), but not at 37°C. In CHC the main feature is the temperature 
dependence of the loss of cations: instead of being around 8-10°C, the 
minimum is around 23°C (Delaunay 2007). The gene responsible for FP was 
mapped at 2q35-q36 (Carella et al. 2004), and then identified in the ABCB6 
gene (Andolfo et al. 2013), encoding the homonymous protein, ABCB6. It 
belongs to the family of ABC transporters with binding cassette for ATP, one 
of the most abundant families of integral membrane proteins. ABCB6 is 
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expressed on the membrane of the erythroid precursors throughout the 
differentiation and on the mature RBC membrane. Instead, CHC is due to 
mutations in SLC4A1 gene; these are gain of function mutations, since they are 
able to transform the band 3 anion exchanger to a cation transporter (Table 1-
3). 
 
1.3 Differential diagnosis of CDAs, HAMDs and related hereditary anemias 
Although the workflow to diagnose HHA is a normal clinical practice, 
differential diagnosis, classification, and patient stratification among CDAs, 
HAMDs and clinically related anemias are often very difficult. Indeed, the 
variety of unspecific and overlapping phenotypes often hampers a correct 
clinical management of the patients. 
Thalassemias and hemoglobinopathies are the first conditions to be excluded. 
The presence of microcytic anemia, pathological Hb electrophoresis and 
positive familial anamnesis can direct the diagnosis toward these disorders. In 
particular, the differential diagnosis with thalassemia is important in suspected 
cases of either CDA IV or CDA variants GATA1-related. Among IBMFS, 
DBA and FA are disorders that most frequently undergo differential diagnosis 
with CDAs. Unlike the CDAs, FA generally presents reduction to absent 
trilinear hematopoiesis, acute myelogenous leukemia or solid tumors; 
moreover, it can also present developmental abnormalities more frequently 
compared to CDAs, particularly CDA I. The positivity to the diepoxybutane 
(DEB) test is a very sensitive and specific tool for guiding FA diagnosis 
(Chirnomas and Kupfer 2013). Similarly to CDAs, DBA presents as isolated 
inherited red cell production failure. However, conversely to CDAs, DBA BM 
exhibits reduced proliferation and survival of erythroid progenitors. Moreover, 
growth retardation, congenital malformations and increased HbF levels are 
more frequent features of DBA compared to CDAs. Increased activity of 
erythrocyte adenosine deaminase is a good II level test for establishing the 
diagnosis of DBA (sensitivity 84%, specificity 95%, positive and negative 
predictive values 91%) (Fargo et al. 2013) (Figure 1-8). 
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Figure 1-8. Flow diagram for the differential diagnosis of CDAs and related hereditary 
anemias. The flow diagram shows the main steps (light blue) for guiding the clinical suspicion 
toward the diagnosis of a CDA. Adapted from Gambale et al. 2016. 
 
CDAs can be also misdiagnosed with hereditary hemolytic anemias. For 
example, CDA II shares several clinical findings with hemolytic anemias due 
to red cell membrane defects, such as HS (King et al. 2015). Of note, CDA II 
patients are often erroneously diagnosed as HS, and consequently, they 
undergo unnecessary splenectomy. The lack of substantial improvement after 
intervention leads to a re-examination of the case, allowing the correct 
diagnosis of CDA II. The most useful pointer to correctly establish the 
diagnosis of CDA II is the inadequate reticulocyte count for the degree of 
anemia. Indeed, the marrow stress is higher in CDA II compared to HS for the 
same Hb level as attested by the increased sTfR levels observed in CDA II 
patients (Russo et al. 2014). Other parameters could be also used for 
distinguishing both conditions. For example, the RDW is characteristically 
increased in CDA II, while the Hb distribution width (HDW) is increased in 
HS, resulting in an RDW/HDW ratio that is significantly greater in CDA II 
than in HS (Heimpel and Iolascon 2009). Recently, a new clinical index, 
named BM responsiveness index, has been developed to discriminate a 
hemolytic anemia from ineffective erythropoiesis one. This index resulted to be 
a high sensitive parameter (90.4%) to achieve a clinical diagnosis of CDA II 
(Russo et al. 2014). In addition, other RBC membrane defects as DHS1-2 or 
OHS should be evaluated in the differential diagnosis of CDA I. Both CDA I 
and HST present macrocytosis associated with hemolytic signs. Moreover, it 
has been described as a novel variant of HST due to a de novo band 3 
mutation, transmitted in a dominant fashion, characterized by conversion of 
band 3 from an anion exchanger to a cation transporter, associated with a 
dyserythropoietic phenotype (Iolascon et al. 2009). 
As effect of chronic anemia and hemolytic component, several complications 
are associated to CDAs. The main are: iron loading, gallstones, 
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hyperbilirubinemia, hypersplenism. The variety of unspecific and overlapping 
phenotypes observed in CDA patients, even in those sharing the same genetic 
pathogenesis, often hampers a correct clinical management of affected 
individuals. Beyond achieving a definitive diagnosis, knowing the genetic basis 
of these patients can be valuable also for guiding treatment. 
 
1.4 Second-generation DNA sequencing 
Second-generation sequencing technologies, commonly referred to as 
NGS, are based on massive parallel sequencing of millions of DNA templates 
through cycles of enzymatic treatment and image-based data acquisition. The 
major current application of NGS in diagnostics is through design of disease 
specific panel, named targeted-NGS (t-NGS), which targets a group of selected 
genes. T-NGS is faster and cheaper than other NGS technologies, such as 
exome sequencing, especially for the analysis of certain distinct disease 
phenotypes or for the differential diagnosis of overlapping clinical conditions. 
For the past 25 years, dideoxy DNA Sanger sequencing and fluorescence based 
electrophoresis technologies, known as the first-generation technology, were 
the gold standard for somatic and germline genetic studies, as well as for 
diagnosis of genetic diseases. However, these methods are expensive and have 
low throughput owing to implementation on single amplicons. Because of the 
limited adaptability of automated Sanger sequencing, there was a need for new 
and improved technologies for sequencing large numbers of human genomes at 
the same time by using various strategies that rely on a combination of 
template preparation, sequencing and imaging, genome alignment, and 
assembly methods. After almost three decades, NGS was developed. This 
technology of high-throughput sequencing has provided a large impetus for de 
novo sequencing, resequencing, exome sequencing, transcriptome profiling, 
methylation profiling, and metagenomics studies (Desai and Jere 2012). NGS 
is a very versatile technology, applicable to various questions either in basic 
research or in clinical research. Indeed, the broadest application of NGS is the 
resequencing of human genomes to enhance the understanding of how genetic 
differences affect health and disease. For this purpose, NGS has reached an 
adequate level of evolution as much to be considered as robust enough for 
clinical applications, mainly for discovering new genes underlying monogenic 
and/or multifactorial diseases. Indeed, over the past decade, NGS has led to an 
exponential increase in our understanding of the genetic basis of Mendelian 
diseases. More recently, NGS has been successfully deployed in the clinics, 
with a reported diagnostic yield of ~25 % (Jamuar and Tan 2015). 
Sequencing technologies include a number of methods that are gathered 
broadly as template preparation, sequencing and imaging, and data analysis. 
The unique combination of specific protocols distinguishes one technology 
from another and determines the type of data produced from each platform. 
The flowcharts of library preparation for NGS sequencing are quite similar: 
28 
 
1. Templates preparation: this step requires a fragmentation of genomic DNA 
into smaller size and the creation the DNA libraries, followed by in vitro 
ligation of templates to common adaptor sequences on a solid surface or 
support. 
2. Clonally amplified templates: the generation of clonally clustered amplicons 
can be achieved by several approaches. After the successful amplification and 
enrichment, beads, representing millions of PCR, can be immobilized with 
various strategies in a polyacrylamide gel on a standard microscope slide or 
solid surface. 
3. Sequencing and imaging: the sequencing reaction consists of alternating 
cycles of enzyme-driven biochemistry and imaging-based data acquisitions. 
The methods for sequencing provide several protocols, such as cyclic 
reversible termination, sequencing by ligation, pyrosequencing, and real-time 
sequencing 
4. Genome alignment and assembly: after generation of NGS reads, the 
alignment to a known reference sequence or assembled de novo is performed 
(Shendure and Ji 2008). 
The major advance offered by NGS is the ability to produce an enormous 
volume of data cheaply. While automated Sanger sequencing produced a 
maximum of approximately six Megabase (Mb) of DNA sequences per day 
(low throughput), the amount of NGS works around 450-50000 Mb of DNA 
sequences per day, based on platform used. The lower cost per base of NGS 
and the ability to sequence millions of reads in parallel, allowing for 
simultaneous analysis of a large number of genes, give to this technology other 
benefits. In the end, with NGS technologies the amount of DNA to be 
sequenced is no longer a barrier to launching a new or expanded clinical test. 
The advantages of second-generation DNA sequencing are currently offset by 
several disadvantages. First, the most prominent of these include read-length: 
for all of the new platforms, read-lengths are currently much shorter than 
conventional sequencing (35-400 nucleotides compared to 600-1000 in length 
of automated Sanger sequencing). Second, raw accuracy, on average, of base-
calls generated by the new platforms are at least tenfold less accurate than 
base-calls generated by Sanger sequencing (1/100-10000 nucleotides compared 
to 1/10000-100000 of conventional sequencing). Despite their weaknesses, 
improvements in these technologies promise to meet the technical requirements 
and strict quality standards for clinical diagnostic practises including analytical 
sensitivity, reproducibility and cost effectiveness. Next-generation sequencing 
includes several high-throughput sequencing approaches: 
- Targeted sequencing and gene panel sequencing involve sequencing of 
selected parts of the genome and/or of selected known/candidate disease-
causing genes. This approach is especially suitable for the diagnosis of 
genetically heterogeneous disorders. 
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- Whole-exome sequencing (WES) targets sequencing of the exome, which 
constitutes 1-2% of the human genome. The application of whole-exome 
sequencing in diagnostics and research has enabled the discovery of novel 
disease genes. 
- Whole-genome sequencing is the sequencing of the entire genome, including 
non-coding, regulatory DNA regions. 
- RNA sequencing, also called whole transcriptome shotgun sequencing, uses 
NGS for both mapping and quantifying RNA in a biological sample 
 
1.5 Targeted-next generation sequencing 
The major current application of NGS in diagnostics is through disease-
targeted tests for which multiple causal genes are known. The combination of 
high-throughput and relatively small DNA target selection allows for many 
genes and samples to be processed simultaneously, making it a reliable solution 
for the processing of large sample numbers in a diagnostic laboratory. Several 
t-NGS panels have been already launched and actually used in diagnostic 
practice for different disorders (Table 1-5). 
 
Table 1-5. Examples of targeted available designs for clinical practice 
Disease area Disease type 
Number of 
genes 
Cancer Hereditary cancers (breast, colon, ovarian) 10–50 
Cardiac disorders 
Cardiomyopathies 
Arrhythmias (long QT syndrome) 
Aortopathies (Marfan’s syndrome) 
50–70 
10–30 
10 
Immune disorders  
Severe combined immunodeficiency syndrome 
Periodic fever 
18 
7 
Neurological, 
neuromuscular and 
metabolic disorders 
Ataxia 
Congenital disorders of glycosylation 
Dementia (Parkinson’s and Alzheimer’s diseases) 
Developmental delay, autism, intellectual disability 
Epilepsy 
Hereditary neuropathy 
Microcephaly 
Mitochondrial disorders 
Muscular dystrophy 
40 
23-28 
32 
30-150 
53-130 
34 
11 
37-450 
12-45 
Sensory disorders 
Eye disease (retinitis pigmentosa) 
Hearing loss and related syndromes 
66–140 
23-72 
Others 
Rasopathies (Noonan’s syndrome) 
Pulmonary disorders (cystic fibrosis) 
Short stature 
10 
12-40 
12 
 
The available disease-targeted panels comprise from ten to hundred 
genes. Some panels contain many genes that can give rise to indistinguishable 
presentations, while other panels have been developed with the aim to diagnose 
diseases with overlapping phenotypic presentations. 
The general principle of t-NGS provides for specific probes carefully designed 
to target regions of interest relevant to genetically heterogeneous disease 
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phenotypes, for which essential is the differential diagnosis. T-NGS is faster 
and cheaper than other NGS technologies, leads to a higher sequencing 
coverage, and, therefore, highly accurate DNA variant calling for the region of 
interest. Consequently, considerable effort has been dedicated to develop 
‘target-enrichment’ methods, in which genomic regions are selectively 
captured from a DNA sample before sequencing. The development of targeted 
technology offers various methodological enrichment approaches to construct 
and enrich a DNA library and use both PCR and/or hybridization as mode of 
target selection. First, the classic PCR approach to library generation requires 
amplification of target regions, pooling, concatenation, shearing and ligation of 
adaptors and sequencing primers. Secondary one, droplet based microfluidic 
technologies have evolved to facilitate high-throughput PCR in picoliter 
droplets. With hybridization-based methods, libraries are constructed by 
shearing total gDNA followed by adaptor ligation and hybridization to 
oligonucleotides that are complementary to the desired target. Hybridization 
can be performed either on a solid surface array, on a filter, or by hybridization 
in solution. A third general approach to target selection uses molecular 
inversion probes, which consist of two primers linked together by a backbone 
and, similar to PCR, bind to specific target DNA. Gap filling, ligation, and 
enrichment steps follow this (Mamanova et al. 2010). There are several 
parameters by which the performance of each enrichment can be monitored, 
which vary from one approach to another:  
- sensitivity, or the percentage of the target bases that are represented by one or 
more sequence reads; 
- specificity, or the percentage of sequences that map to the selected targets; 
- uniformity, or the variability in sequence coverage across target regions; 
- reproducibility; 
- cost and ease of use; 
- amount of DNA required per experiment, or per Mb of target. 
Finally, different types of platforms, known as “bench top” sequencers, have 
also been developed specifically for high-throughput sequencing of targeted 
technologies: Ion Torrent PGM (Life Technologies Ltd, Paisley, UK), 454 GS 
Roche Junior (Roche Applied Science, Indianapolis, IN), and the Illumina 
MiSeq (Illumina, San Diego, CA). 
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2. Aims of the study 
 
The variety of unspecific and overlapping phenotypes observed in HHA 
patients, even in those sharing the same genetic pathogenesis, often hampers a 
correct clinical management of affected individuals. The primary aim of our 
study was the development of a fast, accurate, reliable and cost effective 
diagnostic/prognostic tool for HHA based on t-NGS. Indeed, HHA refers to a 
highly heterogeneous group of inherited rare anemias in which differential 
diagnosis, classification, and patient stratification are often very difficult. 
Beyond achieving a definitive diagnosis, knowing the genetic basis of these 
patients can be valuable also for guiding treatment. In order to evaluate the 
reliability of this approach, we firstly performed a t-NGS pilot study including 
10 known causative genes of two HHA sub-groups, CDAs and HS. 
Subsequently, we created a second t-NGS gene panel, named RedPlex, 
composed by 34 loci causative or candidates of CDAs, HS and HST. 
The t-NGS approach also allowed the identification of “polygenic” conditions, 
i.e. patients in which the phenotypic variability could be explained by the 
presence of modifier variants associated to causative mutations. Thus, the 
secondary aim of this project was the study of the interaction between mutated 
genes in HHA patients. We particularly focused on the regulatory network 
GATA1-mediated on SEC23B gene in CDAII patients with peculiar clinical 
phenotypes or those with incomplete mutation pattern in SEC23B. 
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3. Materials and Methods 
 
3.1 Patients and genomic DNA preparation 
Diagnosis was based on history, clinical findings, laboratory data, 
morphological analysis of peripheral blood and/or aspirated bone marrow. For 
CDAII patients the hypoglycosylation of band 3 was evaluated by SDS-PAGE, 
whenever possible. For HS/HST patients, diagnosis was also based on indirect 
tests (OF, AGLT50, EMA binding) as well as on ektacytometry. Whenever 
possible, RBC membrane proteins were analysed by SDS-PAGE. We enrolled 
a first set of 13 HHA patients from 12 unrelated families for the pilot study, six 
out them with a well-defined phenotype and genotype annotation. Particularly, 
molecular diagnosis in two HS and four CDA patients was already established. 
The second set was composed of 32 HHA patients from 27 unrelated families. 
Samples were obtained after informed consent for the studies, according to the 
Declaration of Helsinki. Relatives were also enrolled. Local university ethical 
committees approved collection of patient’s data from Medical Genetics 
Ambulatory in Naples (University Federico II, DAIMedLab). 
Genomic DNA preparation, mutational search, oligonucleotide primers design 
and direct sequencing were performed as previously described (Russo et al. 
2010). Sequence primers are available on request (russor@ceinge.unina.it). 
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the 
A of ATG translation initiation codon in the reference sequence (Ensembl 
transcript ID), according to the nomenclature for the description of sequence 
variants of Human Genome Variation Society (www.hgvs.org/mutnomen). The 
initiation codon is codon 1. In order to evaluate the quality of the extracted 
gDNA before the fragmentation, samples were quantified by NanoDrop 2000 
(Thermo Scientific, Italy). Then, gDNA was loaded on 0.8% DNA agarose gel 
electrophoresis. 
 
3.2 Custom target enrichment 
 We created two t-NGS gene panels: (1) the first, the pilot study design, 
including only 10 genes causative of HS and CDAs; (2) the second, named 
RedPlex, composed by 34 loci causative or candidates of HHA. 
Pilot study and RedPlex designs 
For the first gene panel 10 causative genes of both CDAs and HS were selected 
(Table 3-1). For the probe design, coding regions, 5’UTR, 3’UTR, 100 bp 
flanking splice junctions were selected as regions of interest (ROI). The 
sequences corresponding to the genomic regions of ROI were uploaded to the 
web-based tool SureDesign (https://earray.chem.agilent.com/suredesign.htm, 
Agilent Technologies, USA). Sequence length was set at 100×2 nucleotides, 
and the predicted target size amounted to 236 target regions (87594 bp). For 
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the second gene panel 34 causative/candidate genes of CDAs, HS and HST 
were included (Table 3-1). Similarly to the first panel, all coding regions, 5’ 
and 3’UTRs, and 100 bp flanking splice junctions were included as ROI in the 
electronic design. Sequence length was set at 150×2 nucleotides, and the 
predicted target size amounted to 538 regions (239.764 kb). The coordinates of 
all the sequence data were determined using NCBI build 37 (GRCh37/hg19). 
 
Table 3-1. Target genes in HaloPlex Design 
Target ID ENST - GRCh37 Regions 
Coverage 
(%) 
High Coverage
§
 
(>= 90%) 
Low Coverage
§
 
(< 90%) 
ABCB6 ENST00000265316 9 100 9 0 
ABCG5 ENST00000260645 11 100 11 0 
ABCG8 ENST00000272286 10 100 10 0 
ADD2 ENST00000264436 16 100 16 0 
ANK1 ENST00000347528 41 100 41 0 
ATP11C ENST00000327569 30 100 30 0 
ATP2A2 ENST00000308664 18 99.88 18 0 
C15ORF41 ENST00000566621 12 99.81 12 0 
CDAN1 ENST00000356231 17 99.4 17 0 
EPB41 ENST00000373800 19 100 19 0 
EPB42 ENST00000300215 13 100 13 0 
EPB49 ENST00000265800 11 100 11 0 
FOG1 ENST00000319555 9 99.89 9 0 
FOXL1 ENST00000320241 1 100 1 0 
GATA1 ENST00000376670 5 100 5 0 
GATA2 ENST00000487848 6 100 6 0 
GFI1B ENST00000339463 11 100 11 0 
KIF23 ENST00000260363 19 100 19 0 
KLF1 ENST00000264834 3 100 3 0 
MPP1 ENST00000369534 1 100 1 0 
PIEZO1 ENST00000301015 33 100 33 0 
RHAG ENST00000371175 10 100 10 0 
SAR1A ENST00000373241 8 99.8 8 0 
SEC23B ENST00000377475 20 100 20 0 
SEC31A ENST00000395310 26 100 26 0 
SLC12A4 ENST00000316341 15 100 15 0 
SLC12A6 ENST00000354181 25 99.97 25 0 
SLC12A7 ENST00000264930 23 99.97 23 0 
SLC2A1 ENST00000426263 7 99.3 7 0 
SLC4A1 ENST00000262418 14 99.86 14 0 
SPTA1 ENST00000368147 48 99.95 48 0 
SPTB ENST00000389721 31 99.84 31 0 
STOM ENST00000286713 7 100 7 0 
TMOD1 ENST00000259365 10 100 10 0 
§
Number of regions with High or Low coverage 
In bold are highlighted the genes included in the first panel (pilot study design) 
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Sample preparation, capturing and enrichment 
Sample preparation was performed following the instruction’s manufacturer for 
HaloPlex Target Enrichment kit for Illumina Sequencing - Custom Design 
from 1-500kb, p/n G9901A (protocol version D - Agilent Technologies). All 
procedures require the use of a control gDNA provided to kit (Enrichment 
Control DNA, ECD). Briefly, each DNA sample (225 ng), included the ECD 
DNA, is fragmented in two specific double-digestion reactions defining the 
ROI at 37°C for 30 minutes. Validation of the digestion is performed on the 
ECD reactions using 2100 Bioanalyzer system analysis with 2100 Expert 
Software (version B.02.07, Agilent Technologies) and High Sensitivity DNA 
Assay Kit (p/n 5067-4626, Agilent Technologies). Because of amplicon 
redundancy, target region is covered many times. Then, target fragments are 
mixed with a primer cassette and custom HaloPlex biotinylated probes, which 
are specific for target regions and contain Illumina adapters and index 
sequences. During the hybridization (at 54°C for 3 hours), the probes 
circularize the targeted DNA fragments. Correctly hybridized fragments form a 
nicked double strand DNA structure with the HaloPlex probe. Thus, 
circularized target DNA-HaloPlex probe hybrids are captured by streptavidin 
beads (HaloPlex Magnetic Beads, Agilent Technologies) and then washed. 
Subsequently, circularized HaloPlex probe-target DNA hybrids are ligated with 
DNA ligase to close nicks between the target fragment and the primer cassette, 
at 55°C for 10 minutes. Then, the circularized hybrid is amplified by PCR with 
Herculase II Fusion Enzyme (Agilent Technologies), using an exclusive primer 
composed by two regions, one complementary to the target and the other useful 
for sequencing. Finally, each amplicon contains one target insert surrounded by 
the Illumina paired-end sequencing elements, the sample index and the library 
bridge PCR primers. The amplified target DNA is purified using Agencourt 
AMPure XP beads (Beckman Coulter Genomics, USA) and 10 mM Tris-HCl 
buffer (pH 8.0). After target enrichment, validation and quantification of PCR 
library are performed by 2100 Bioanalyzer system analysis using High 
Sensitivity DNA Assay Kit (Agilent Technologies) before sequencing. The 
amplicon size ranges between 175 and 625 bp, with the majority of products 
between 225-525 bp. 
 
3.3 Sequencing and data analysis 
 High-throughput sequencing was performed by Illumina Hiseq2000 
platform for the pilot gene panel and Illumina NextSeq 500 for the RedPlex 
gene panel. Agilent SureCall software (v 3.0.3.1, Agilent Technologies) was 
used for bioinformatic and computational analyses. Analysis in SureCall starts 
from raw reads; after removal of the adaptor sequences, the reads are aligned to 
GRCh37/hg19 human reference sequence with Burrows - Wheeler aligner 
(BWA) included in SureCall software. SAMTools are used to recalibrate the 
base call quality scores, perform local realignment, and index the reads for 
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improved performance. SAMTools are also used to identify mutations and to 
assess the significance of the mutations. Each of these was evaluated by 
SureCall software based on its location, amino acid change, effect on protein 
function (SIFT), and impact on structure and function of the protein (PolyPhen-
2). Moreover, mutations information were aggregated from various public 
sources, including NCBI, COSMIC (Catalog of Somatic Mutations in Cancer), 
PubMed, and Locus Specific Databases (HGVS). The significance of the 
mutations were evaluated by the mutational classifier following customized 
guidelines. The custom categorization was based on the criteria shown in the 
Table 3-2. The SureCall output for each patient is a genome viewer and a 
mutation table, from which originates a report file. 
 
Table 3-2. SureCall custom categorization 
Category I 
Coding variants 
Any missense mutation 
Nonsense or a frame shift mutation 
Introduction of a stop codon 
Results in codon change 
Results in codon insertion 
Results in codon change and codon deletion 
Results in codon change and codon insertion 
Results in codon deletion 
Missense mutation of the normal stop codon 
Mutates in the initiation codon (ATG) 
Deletes nucleotide(s) that lead(s) to a shift of reading frame 
Deletes exon which results in shift of reading frame 
Is non-synonymous coding variant in start 
Is non-synonymous coding variant in stop 
Is non-synonymous coding variant 
Is synonymous coding variant in stop 
Is synonymous coding variant in start 
Is synonymous coding variant 
In-frame amino acid insertion/deletion 
In-frame exon deletion 
Category II 
Splicing variants 
Located within a splice consensus sequence 
Is splice site donor 
Is splice site acceptor 
Alters the sequence at a splice junction 
Likely to produce a cryptic splice site 
Category III 
Regulatory variants 
Modifies UTR 3' 
Modifies UTR 5' 
Deletes UTR 3' 
Deletes UTR 5' 
Likely to affect transcription 
Category IV 
Intronic variants 
Sequence changes that occur in the intron 
Is inter-genic 
Is intronic variant 
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The mutations were divided in four categories, each one composed by several 
sub-types. The first category includes coding variants, such as non-
synonymous coding variants, nonsense and/or frame shift mutations. The 
second category includes splicing variant mutations located in consensus, 
donor or acceptor sites, and mutations that generate a novel cryptic splice site. 
The third category comprises the regulatory variants, modifying and/or deleting 
both 3’ and 5’ UTRs, and the mutations affecting the transcription levels. 
Finally, the last category embraces the intronic variants. 
Annotated variants were firstly filtered on the basis of their presence in 
variation databases. Indeed, variants with a minor allele frequency (MAF) > 
0.01, as reported by NCBI-dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), 
Exome Variant Server (EVS, http://evs.gs.washington.edu/EVS/), and 1000 
Genomes (http://browser.1000genomes.org/index.html), were excluded. Rare 
and low frequency variants (MAF < 0.01 and 0.05, respectively) were selected. 
Subsequently, we applied a strand bias filtering and we choose a strand bias 
threshold of 0.90. Thus variants with a strand bias > 0.90 were also excluded. 
Finally, the remaining variants were prioritized by using the scores provided by 
the prediction tools PolyPhen2 and SIFT for coding variants. Prediction 
analysis for splice sites mutations was also performed by web server tool 
Human Splicing Finder (http://www.umd.be/HSF/), as previously described 
(Russo et al. 2013b). 
All focused variants were confirmed by Sanger sequencing and by the analysis 
of inheritance pattern. The validations were performed using 50 ng of genomic 
DNA. Custom primers were designed by Primer3 program (Primer3 v. 0.4.0, 
freeware online). Direct sequencing was performed using the Dye Terminator 
Cycle Sequencing FS Ready Reaction Kit (Applied Biosystems) and a 373A 
DNA sequencer (Applied Biosystems). 
 
3.4 Gene and protein expression analysis 
RNA isolation and reverse transcription 
Total RNA was extracted from peripheral blood mononuclear cells (PBMCs) 
and cell lines using Trizol reagent (Life Technologies). Synthesis of cDNA 
from total RNA (2 μg) was performed using cDNA synthesis kit (Applied 
Biosystems, Milan, Italy). 
Quantitative real-time PCR analysis  
Quantitative RT-PCR (qRT-PCR) using Power SYBR Green PCR Master Mix 
(Applied Biosystems) was performed to evaluate the gene expression of 
GATA1 and SEC23B genes. Samples were amplified on Applied Biosystems 
7900HT Sequence Detection System using standard cycling conditions. The 
primers were designed by the Primer Express 2.1 program (Applied 
Biosystems). β-actin was used as internal control. Relative gene expression 
was calculated by using the 2
-ΔCt
 method, while the mean fold change = 2
-
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(average ∆∆Ct)
 was assessed using the mean difference in the ∆Ct between the gene 
and the internal control (Russo et al. 2013b). Primer sequences are available 
upon request (russor@ceinge.unina.it). 
Protein isolation and western blotting analysis 
Protein extraction from PBMCs and western blotting (WB) were performed as 
previously described (Andolfo et al. 2010; Russo et al. 2013b). Particularly, 30 
µg of total extract proteins was loaded into each lane and was separated by 
10% SDS PAGE bisacrylamide gel, followed by transfer to PVDF membranes 
(Biorad, Milan, Italy). A specific rabbit anti-SEC23B antibody (1:500) 
(BioLegend, San Diego, CA) and anti-GATA1 antibody (1:500) (ab11963 - 
Abcam, Cambridge, UK) were used. Mouse anti-β-actin antibody (1:5000) 
(Sigma-Aldrich, Milan, Italy) was used as the control for equal loading. Semi-
quantitative analysis of protein expression was performed as previously 
described (Persico et al. 2008). The bands were quantified by densitometry to 
obtain an integral optical density value, which then was normalized with 
respect to the β-actin value. 
 
3.5 Vector cloning 
SEC23B promoter characterization 
The in silico analysis of human SEC23B (HuSEC23B) upstream region 
(chr20:18487188-18491479: 4292 bp from ATG) has been performed by 
ENCODE web tool implemented in the UCSC Genome Browser 
(http://genome.ucsc.edu/). Prediction analyses for CpG island were performed 
by CpG Islands Track (UCSC Genome Browser) and by EMBOSS Cpgplot, at 
EMBL-EBI website (http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/). 
The hypothetical promoter region of SEC23B gene (3450 bp from ATG) has 
been divided into 10 overlapping fragments (HuSEC23B/3.44, 
HuSEC23B/2.52, HuSEC23B/2.14, HuSEC23B/1.75, HuSEC23B/1.28, 
HuSEC23B/0.99, HuSEC23B/0.81, HuSEC23B/0.61, HuSEC23B/0.45, 
HuSEC23B/0.21), amplified from genomic DNA (figure 3). Each construct 
was purified with QIAquick PCR Purification Kit (Qiagen, Milan, Italy), 
cloned upstream the luciferase gene into PGL3 vector (Life Technologies) in 
the Hind III and Xho I sites. Two-primer site-direct PCR mutagenesis was used 
to mutagenize the GATA1 binding sites (GATA1bs) in the two fragments 
HuSEC23B-2475 and HuSEC23B-463. The amplified region and ligation 
boundaries were verified by direct sequencing, as previously described. 
Cloning of GATA1 cDNA product into expression vector 
GATA 1 cDNA product (BC009797_Clone ID 4048082, Invitrogen) was 
amplified from pDNR-LIB vector, purified with QIAquick PCR Purification 
Kit (Qiagen) and cloned into pcDNA3.1 vector (Invitrogen, Milan, Italy) in the 
EcoRV and XhoI sites. All plasmids were transformed into the DH5α bacterial 
strain (Invitrogen) and subsequently purified with the QIAprep Miniprep Kit 
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(Qiagen). Direct sequencing was performed as previously described. Two-
primer site-direct PCR mutagenesis was used to introduce GATA1-associated 
missense mutations G208R, R216W, D218G, and V205M. The amplified 
region and ligation boundaries were verified by direct sequencing. 
 
3.6 Cell cultures and transfection 
HEK-293 and K562 cells (ATCC, Manassas, VA, USA) were maintained 
according to the manufacturer’s instructions. HuSEC23B plasmids were 
transfected (2 µg/well) using the X-tremeGENE HP DNA Transfection 
Reagent (Roche, Milan, Italy) according to the manufacturer’s procedures. The 
cells were collected 48h after the transfection to luciferase assays. Co-
transfection of GATA1bs/HuSEC23B-2475 and -463 mutants (2.5 µg/well) 
and GATA1 WT (2.5 µg/well) was performed using the X-tremeGENE HP 
DNA Transfection Reagent (Roche) according to the manufacturer’s 
procedures. The cells were collected 48h after the transfection to luciferase 
assays. Similarly, co-transfection of GATA1 mutants (GATA1/G208R, 
GATA1/R216W, GATA1/D218G, and GATA1/V205M) (2.5 µg/well) and the 
HuSEC23B/3.44 (2.5 µg/well) in HEK-293 cell line was performed using the 
X-tremeGENE HP DNA Transfection Reagent (Roche) according to the 
manufacturer’s procedures. The cells were collected 48h after the transfection 
to luciferase assays. 
Erythroid differentiation of K562 and Hel cells 
Fifty μM hemin (Sigma-Aldrich) was added to the culture medium of the wild-
type K562 and Hel cells (2x10
5
/mL). Samples were collected at days 6 after 
hemin addition. Erythroid differentiation was assessed by FACS analysis for 
transferrin receptor 1 (CD71) and glycophorin A (CD235A) as previously 
described (Andolfo et al. 2010).  
 
3.7 Chromatin immunoprecipitation assay 
The hypothetical GATA1 binding sites in the promoter region of the SEC23B 
gene has been predicted by the software tool MatInspector, implemented in 
Genomatix web server 
(http://www.genomatix.de/online_help/help_matinspector/matinspector_help.h
tml) and by PROMO at the ALGGEN server (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). Chromatin 
immunoprecipitation (ChIP) studies were performed by Immunoprecipitation 
Kit - Dynabeads, following the manufacturer’s instruction (Life Technologies). 
Isolated chromatin from K562 and HEL cells at 6 days of erythroid 
differentiation was immunoprecipitated using control immunoglobulin G or 5 
μg rabbit polyclonal GATA1 antibody (ab11963 - Abcam). Ten μl of 
immunoprecipitated DNA were used for the qRT-PCRs, to detect the presence 
of specific DNA segments. We used ETO (Ajore R et al. 2010) as a positive 
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control and a not-binder GATA1-sequence of the HuSEC23B promoter as a 
negative control. 
 
3.8 Promoter assay 
Luciferase assays with HuSEC23B deletion mutant constructs were performed 
in the HEK-293 and K562 cell lines. Cells were grown according to the 
manufacturer’s protocol. For the promoter assay, HEK-293 and K562 cells 
were plated in 6-well plates and transfected with the HuSEC23B deletion 
mutants using Extreme gene (Roche). Transfected cells were harvested after 48 
hrs. The PRL-CMV vector (100 ng) was used for normalization. Luciferase 
activities were analysed using a Dual Luciferase Reporter Assay system 
(Promega). 
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4. Results 
 
4.1 Pilot study 
 Thirteen HHA patients from 12 unrelated families were included in the 
pilot study. Overall clinical features and diagnostic suspicion for each subjects 
was summarized in Table 4-1. 
 
Table 4-1. Clinical data of 15 HHA patients included in the pilot study 
Patient ID 
Gender 
(M)ale/(F)emale 
Ethnicity Consanguinity Diagnostic suspicion 
HHA1 F France No CHC 
HHA2 F United Kingdom No HPP 
HHA3 M Italy No HS 
HHA4 F Italy No HS 
HHA5 M Egypt No HS 
HHA6 M Italy Yes
1
 HS 
HHA7 M France No HS 
HHA8 M Italy No CDA II 
HHA9 F Italy No CDA II 
HHA10 M Turkey Yes
2
 CDA I 
HHA11 F Czech Republic No CDA IV 
HHA12 M Italy No Healthy subject 
HHA13 F Italy No HS 
HHA14 M Italy - CDA II/HS 
HHA15 F Italy - Healthy subject 
1
Parents are distant relatives; 
2
Parents are first cousins  
In bold are highlighted the patients with known molecular diagnosis 
In italics are indicated subjects from the same family 
 
Among 13 probands, six showed a clinical suspect of HS. Among these, 
HHA14 was firstly diagnosed as CDA II because of increased value of sTfR 
(11.10 mg/L) and the presence of ineffective erythropoiesis (Hb: 4.8 g/dL with 
inadequate reticulocyte absolute count, 114500/µL). Because of uncertain 
hematologic data and in presence of a positive family history (HHA14’s 
mother, HHA13, was suspected as HS), HS indirect tests were performed. OF, 
AGLT50 and EMA binding tests resulted suggestive of HS in HHA14 and in 
HHA13, except for EMA binding that was normal. Among the remaining 
seven patients, five were already diagnosed at both clinical and molecular 
level. Particularly, HHA1 and HHA2 were diagnosed as CHC and HPP, 
respectively, while HHA9, HHA10, and HHA11 were diagnosed as CDAs. 
HHA9 and HHA10 were firstly misdiagnosed as HS, and they underwent 
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splenectomy without any improvements. Moreover, BM examination in HHA9 
highlighted erythroid hyperplasia with >10% of mature binuclear erythroblasts, 
while SDS-PAGE analysis showed the hypoglycosylation of band 3. On the 
other side, HHA10 exhibited internuclear chromatin bridges between 
erythroblasts at BM light microscopy examination. Almost all CDAs patients 
received few transfusions during their lifespan, but HHA11 resulted 
transfusion-dependent. 
Based on HaloPlex Sure Design, the design for the pilot study on 10 genes 
encompassed 211 target regions within 87.383 Kb. After the submission of the 
design, the resulting amplicons were 5131 with total sequenceable size regions 
of 148.94 Kb. The mean sequencing coverage of target regions was 99.34% ± 
0.48%. The mean percentage of all reads in covered regions was 93.42% ± 
3.21%. The mean percentages of analyzable target region bases with at least 20 
and 100 reads were 99.79% ± 0.09% and 99.40% ± 0.45%, respectively. The 
insufficiently covered regions were found mostly outside coding regions. For 
each patient target gene variants were in the range 55-105; among these 5-13 
were coding variants (Table 4-2).  
 
Table 4-2. Total and selected variants 
Category  No. of variants
†
 
Selected variants 1-5 
Focused variants 
 
Coding mutations related to clinical phenotype 0−2 
Coding mutations modifying clinical phenotype 0-3 
Coding mutations unrelated to the clinical phenotype 0−3 
Intronic and regulatory gene variants 0-2 
Total variants
§
 
 
Total gene variants 62−122 
Off-target gene variants 0−2 
Target gene variants 55-105 
Intronic and regulatory gene variants 48-92 
Coding gene variants 5-13 
†
Number of variants refers to the range observed (from lowest to highest number of variants) in the 
15 cases with MAF<0.01 or without MAF 
§
Number of all variants refers to the range observed (from lowest to highest number of variants) in 
the 15 cases without any filters 
 
Beyond to establish a definitive diagnosis for HHA patients, this approach 
highlighted the presence highlighted the presence of phenotype modifier 
mutations in those cases with overlapping phenotypes (Figure 4-1). 
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Figure 4-1. T-NGS data from pilot study on 13 patients with HHA. The charts on the left 
and on the right represent in the column the patients analyzed by t-NGS and in row the genes 
analyzed. On the left are indicated all the focused variants (variants filtered on the basis of 
MAF and strand bias). The grey square indicates the presence of at least one variant in the 
gene, while the number 2 indicates the presence of two variants in the same gene. On the right 
are shown the clinically related/modifier variants selected among the focused one on the basis 
of clinical phenotype and predictions by bioinformatic tools. 
 
HHA1, HHA2, HHA9, HHA10 and HHA11 were previously diagnosed at 
molecular level. HaloPlex approach was able to confirm the molecular 
diagnosis in all of these patients. Particularly, HHA1 showed the variant 
p.Gly796Arg in SLC4A1 gene in heterozygous state, accordingly to the clinical 
suspect of CHC. HHA2 patient revealed the presence of αLELY 
polymorphisms (rs3737515 and rs28525570 in compound heterozygous state) 
in SPTA1; however, a previously described large deletion spanning from two 
exons in SPTA1 gene was not identified (Iolascon et al. 2011). In HHA9 we 
confirmed the presence of two causative SEC23B mutations, p.Arg14Trp 
(rs121918222) and p.Glu109Lys (rs121918221). Accordingly to the clinical 
suspicion of CDA I, we found two mutations in CDAN1 gene in HHA10 
patient: the missense p.Pro86Ser in heterozygous state and a new intronic 
variant c.774-89G>T, which is predicted to alter the splice site of the nearby 
exon. Of note, in this case HaloPlex approach was able to identify a non-
coding variant far from splice site. Finally, HHA11 patient presented one 
missense mutation in KLF1 p.Glu325Lys (rs267607201), in agreement with the 
clinical suspicion (Table 4-1). 
Among the remaining seven patients with unknown diagnosis, we were able to 
define the causative genotype in five out them. Two patients, HHA4 and 
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HHA6, resulted undiagnosed. Two probable causative mutations in SPTB were 
identified in HHA3 patient, who had a clinical suspect of HE: p.Arg1737Trp 
(rs149727354) and a novel missense variation, p.Arg52Gln, both in 
heterozygous state. In addition, we reported the αLELY variant in homozygous 
state. In the absence of the parental DNA, we did not define the inheritance 
pattern of these variants. HHA4 patient presented only a synonymous variant 
p.Ser603= (rs139882548) in SEC23B gene, which resulted unrelated to the 
phenotype. Accordingly to the dominant transmission in both HHA5 and 
HHA7 patients, we found a causative mutation, p.Arg568Pro, and a missense 
annotated variant, p.Glu11Asp (rs41273533), in SPTA1 that could explain the 
HS phenotype in both cases. Finally, in the patient HHA8 we confirmed the 
diagnostic suspicion of CDA II/XLTDA; indeed, a missense mutation 
p.Gly208Arg in GATA1 gene was identified, as explained in the next sections 
of the results (Figure 4-1). 
 
4.2 RedPlex study 
Thirty-two HHA patients from 27 unrelated families were included in 
the RedPlex study. Overall clinical features and diagnostic suspicion of HHA 
patients included in this study was summarized in Table 4-3. 
 
Table 4-3. Clinical data of 44 HHA patients included in the RedPlex 
Patient 
ID 
Family 
ID 
Gender 
(M)ale/(F)emale 
Ethnicity Consanguinity 
Diagnostic 
suspicion 
RED1 F1 F Sweden Yes
2
 HST 
RED4 F2 M Italy No HST/CDAs 
RED5 F2 F Italy No HST/CDAs 
RED6 F3 M Oman Yes
1
 HS 
RED9 F3 F Oman Yes
1
 HS 
RED10 F4 F Italy No OHS 
RED11 F5 F Italy No HS/Undefined 
RED12 F6 M Italy No HS/Undefined 
RED14 F7 M Italy No Undefined 
RED17 F8 F Italy No HS 
RED18 F8 M Italy No HS 
RED20 F9 F Italy No HST/CDAs 
RED21 F9 M Italy No HST/CDAs 
RED23 F10 M Italy No CDA I 
RED26 F11 M Australia No CDAs 
RED29 F12 M Turkey Yes
2
 CDA I 
RED30 F13 M United Kingdom No CDA II 
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RED33 F14 M USA Yes
1
 CDA II 
RED34 F15 M Turkey Yes
2
 CDA II 
RED35 F16 M Turkey Yes
2
 CDA II 
RED36 F17 F Turkey No CDA II 
RED37 F18 M Turkey Yes
2
 CDA II 
RED38 F19 M Turkey No CDA II 
RED39 F20 M Turkey Yes
1
 CDA II 
RED40 F21 F Turkey Yes
2
 CDA I 
RED41 F22 F France No DHS 
RED42 F23 F France No DHS 
RED43 F24 F Italy No FP 
RED45 F25 F Germany No DHS 
RED46 F26 M Italy No DHS 
RED47 F26 F Italy No DHS 
RED48 F27 M United Kingdom No DHS 
1
Parents are distant relatives; 
2
Parents are first cousins 
In bold are highlighted the undiagnosed patients 
 
Among the 32 probands, four showed a clinical suspect of HS, nine of HST, 12 
of CDAs and seven showed overlapping phenotypes or undefined condition. 
Based on HaloPlex Sure Design, the design for the RedPlex study on 34 genes 
encompassed 538 target regions within 239.764 Kb. After the submission of 
the design, the resulting amplicons were 8874 with total sequenceable size 
regions of 419.47 Kb. RedPlex panel showed high sensitivity and specificity. 
All regions resulted at high coverage (>= 90%), with a total target coverage of 
99.93 %. Moreover, approximately 97.0% and 90.0% of ROIs were covered by 
at least 100 and 200 reads, respectively. The insufficiently covered regions 
were found mostly outside coding regions. Several non-synonymous variants 
of unknown significance were identified in the largest genes. For the majority 
of patients the molecular findings obtained by RedPlex analysis confirmed the 
clinical suspect, while for other patients the multi-genic approach has modified 
the initial suspicion (Figure 4-2). Indeed, we were able to obtain a conclusive 
diagnosis in 23 out 32 patients (approximately 72%); instead, nine patients 
(RED 10, 14, 17, 18, 20, 21, 23, 26, 35) remained undiagnosed (Table 4-3). We 
also identified some patients showing multiple disease-associated variants 
suggesting complex inheritance, as described in the next section of the results 
(Figure 4-2). 
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Figure 4-2. T-NGS data from RedPlex study on 23 HHA patients. In the column the 
causative/candidate genes analyzed by RedPlex divided according to different HHA 
phenotypes; in the row the investigated patients divided according to their clinical suspicion. 
Dark gray squares highlight variants related to the phenotype or those prioritized as damaging 
by prediction tools. Light gray squares indicate clinically related/modifier variants. In italics 
are indicate relatives of the probands (see Table 4-3). 
 
4.3 Clinical features of HHA8 and RED30 patients 
We functionally investigated both HHA8 and RED30 patients. Both 
showed clinical and biochemical data compatible with the diagnosis of CDA II. 
Clinical features of the two proband are described below, and hematologic 
status of each proband at diagnosis is summarized in Table 4-4. 
 
Table 4-4. Clinical data of HHA8 and RED30 patients 
  HHA8 RED30 
Age at diagnosis (years) 22 48 
Onset symptoms (years) neonatal 40 
Complete blood count 
 
RBC (10
6
/µl) 2.2 
 
Hb (gr/dl) 8.0 10.0 
Ht (%) 22.2 
 
MCV (fl) 89 86 
MCH (pg) 29.0 
 
MCHC (gr/dl) 29.0 
 
Retics % 4.6 
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Absolute retics count (10
6
/L) 17520 102000 
PLT (10
3
/µL) 32.0 198.0 
Biochemical data 
Bc+u/Bu (mg/dl) 2.6/0.7 7.5/0.7 
LDH (U/L) 1121 171 
Hpt (mg/dl) 9.3 11.0 
Ferritin (ng/dl) 313 1157 
IS transferrin (%) 25 85 
Bc, conjugated bilirubin; Bu, unconjugated bilirubin 
Hpt, Haptoglobin 
 
Case1 (HHA8). Twenty-two years old male, third son of healthy non-
consanguineous parents of Italian origin. At birth respiratory distress, 
hemorrhagic manifestations and hypospadias were observed. Family history is 
not indicative for anemia, both brothers were monorchid. At four months old, 
anemia with thrombocytopenia was observed (Table 4-4). During childhood 
two transfusions of packed RBCs and several PLT transfusions were 
performed. Peripheral blood smear shows anisopoikolocytosis and 
hypochromic red cells; some erythroblasts were also present. BM analysis 
revealed dyserythropoiesis with bi- and multi-nucleated erythroblasts. EM 
analysis revealed the presence of double membranes in erythroblasts, a typical 
feature of CDA II, as well as ultrastructural abnormalities in megakaryocytes 
and platelets. Particularly, lack of PLT demarcation membranes, presence of 
cytoplasmic vacuoles, net decreased dense granules were described. 
Thrombocytopenia with some large platelets with fairly normal granulation 
pattern was also observed. At present, the patient does not require transfusions. 
He shows macrocytic anemia (Hb 9.8 g/dl; MCV 100.3fl), with a reticulocyte 
count not adequate to the degree of anemia (150000/µl). The PLT count is very 
low (25000/µl) and petechiae are observed at physical examination. 
Case2 (RED30). Male, 48 years old, one of four children of healthy parents of 
Punjabi origin. Family history is not indicative for anemia or jaundice. At 40 
years he shows jaundice at physical examination. He was previously fit and 
well. Ultrasound scan of the abdomen showed multiple gallstones. A 
subsequent magnetic resonance cholangiopancreatography showed a low signal 
density liver consistent with iron overload. Indeed, ferritin level was 1157 
ng/dl and transferrin saturation 85% (Table 4-4); however no mutations in HFE 
gene were detected. Mild normocytic anemia was observed (Hb 10.0 g/dl, 
MCV 86.1 fl) with a reticulocyte count not adequate to the degree of anemia 
(102000/µl). Platelet count was 198000/µl. Hemolysis was confirmed by low 
level of haptoglobin. No mutations in HBA and HBB genes were found. Deficit 
of pyruvate kinase and G6PD, porphyria, sideroblastic anemia and hepatitis 
viruses (HAV, HBV and HCV) were also ruled out. Blood smear showed 
polychromasia, nucleated red blood cells, some irregular contracted cells and 
spherocytes. BM examination showed hypercellularity with severe 
dyserythropoiesis with multinucleated forms, mild internuclear bridges. No 
changes in leukocytes and megakaryocytes were observed. Iron content in 
47 
 
macrophages was high with many sideroblasts but no evidence of ring 
sideroblasts. EM of BM showed binucleated erythroblasts with double 
membrane and SDS-PAGE highlighted the presence of hypoglycosylated band 
3, a hallmark of CDA II. At 43 years the proband started on regular 
venesections for the high levels of ferritin; Hb level was maintained and he did 
not require blood transfusions. Ferritin level reduced slightly this period. 
Screening for complications of hemochromatosis was also performed. He had a 
liver biopsy which revealed early liver cirrhosis with iron overload. He 
developed diabetes and started on Insulin Lantus. He complained of impotence 
which may also be a complication of his underlying hemochromatosis (FSH 
and LH levels were normal). 
 
4.4 Identification of mutations in GATA1 and SEC23B genes 
We analysed both patients by t-NGS (Figures 4-1, 4-2). The first 
proband HHA8 was hemizygous for the c.722G>A transition in GATA1 gene, 
which results in the aminoacidic substitution p.Gly208Arg; this missense 
mutation has been already described as causative of XLTDA (Del Vecchio et 
al. 2005; Kratz et al. 2008). Accordingly to X-linked inheritance pattern, the 
mutation was inherited from the mother. No additional mutations have been 
found in SEC23B gene (Figure 4-3a).  
 
 
Figure 4-3. GATA1 and SEC23B mutations. (a) Inheritance pattern of GATA1 mutation 
c.722G>A, Gly208Arg, was shown. (b) Proband II.2 showed a digenic inheritance for SEC23B 
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intronic mutation, c.1905+3G>T, and GATA1 c.-71-92G>A rare variant. DNA from relatives 
was not available. (c) Amplification by PCR of the exon region 17-20 of SEC23B cDNA from 
patient II.2 and a control subject (HC). After the PCR, the products were separated on 1.5% 
agarose gel. The top band measures 539 bp, while the bottom band in lane 2 measures 
approximately 377 bp (exon-16 skipped transcript). On the left, sequencing analysis of the 377-
bp PCR product is shown. 
 
RedPlex analysis in the second proband highlighted the presence of a novel 
intronic mutation, c.1905+3G>T, in heterozygous state in SEC23B gene 
(Figure 4-3b). In silico analysis predicted for this nucleotide replacement a 
slight reduction of the score between wild type and mutated donor site 
sequence (ref score=95.15, mut score=91.28, variation=-4.06%). Accordingly, 
amplification of the specific exon regions, encompassing the mutation, of 
SEC23B cDNA from whole blood mRNA of the patient highlighted the 
presence of two bands on agarose gel: one corresponding to the expected size 
fragment (539 bp) and an additional 162-bp shorter transcript, due to the 
skipping of exon 16, as confirmed by sequencing analysis of both cDNA 
products (Figure 4-3c). However, we did not find any other mutation in 
SEC23B gene, so the mutational pattern in this patient resulted incomplete. 
Moreover, we excluded large deletions within the coding region of the gene. 
Interestingly, RedPlex analysis highlighted the presence of a rare nucleotide 
transition c.-183G>A in the 5’upstream region of GATA1 gene. This single 
nucleotide variant (SNV rs113966884) is present in 1000 Genomes project 
(http://www.1000genomes.org/), with a minor allele frequency 0.03, although 
some variations between different populations are observed (Figure 4-4a). We 
evaluated GATA1 expression in healthy subjects stratified according to 
GATA1-rs113966884 genotype: it was shown that allele A is associated to a 
significant reduced expression of GATA1 compared to allele G (p = 0.01). A 
reduced SEC23B expression in control subjects with GATA1-rs113966884 
allele A compared to allele G was observed, albeit not significant (p = 0.15) 
(Figure 4-4b). 
 
 
Figure 4-4. Genetic and functional description of GATA1-rs113966884. (a) Absolute allele 
frequencies of GATA1-rs113966884 SNV in control populations from 1000 Genomes project 
(AFR, African; AMR, Ad Mixed American; ASN, East Asian; EUR, European). (b) Gene 
relative expression of GATA1 and SEC23B genes respect to the reference gene, β-actin, in 48 
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and 27 healthy subjects, respectively, stratified according to the genotype of GATA1-
rs113966884 SNV is shown. Subjects with genotypes AG/AA/A0 showed a reduced 
expression of both genes when compared with genotypes GG/G0 (GATA1: allele G, 
0.03±0.003; allele A, 0.02±0.002 – SEC23B: allele G, 0.12±0.03; allele A, 0.08±0.008). Data 
are presented as mean ± SE. P value has been calculated by Student t test. 
 
4.5 The mutations c.722G>A and c.-183G>A account for a reduced expression 
of GATA1 and SEC23B 
In order to establish the effect of both GATA1 mutations, c.722 G>A 
and c.-71-92G>A, on GATA1 expression we firstly performed a qRT-PCR 
analysis of the gene in the two probands. We observed a marked 
downregulation (approximately 90%) of GATA1-c.722G>A mRNA expression 
in the first proband II.3 compared to healthy subjects (p=0.04). Accordingly, 
his mother I.2, heterozygous for the mutation, showed a reduced GATA1 
expression of approximately 50%. Although sequencing analysis did not reveal 
any additional mutations in the coding sequence of SEC23B gene, expression 
profiling of this gene showed the same reduced trend in the proband II.3 
(p=0.005) and in his mother I.2 (Figure 4-5a). WB analyses revealed 
comparable results for both mutations (Figure 4-5c). 
 
 
Figure 4-5. Analysis of the effect of GATA1 mutations on GATA1 and SEC23B 
expression. (a) GATA1 and SEC23B relative expression respect to HCs (n = 8) is shown. 
GATA1-G208R patient II.3 and in his mother I.2 showed a reduced expression of both genes 
GATA1 (HCs, 2.29±0.60; I.2, 1.20±0.04; II.3, 0.20±0.02) and SEC23B (HCs, 1.13±0.18; I.2, 
0.26±0.004; II.3, 0.06±0.01). Data are presented as mean ± SE. P value has been calculated by 
Student t test. (b) GATA1 and SEC23B relative expression of patient II.2 respect to HCs (n = 8) 
is shown. Patient II.2 showed a slight reduction of GATA1 gene expression (HCs, 1.04±0.11; 
II.2, 0.74±0.09) and a marked reduction of SEC23B expression (HCs, 1.02±0.08; II.2, 
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0.65±0.05). Data are presented as mean ± SE. P value has been calculated by Student t test. (c) 
WB analysis highlighted a marked reduced expression of GATA1 and SEC23B in both patients 
compared to HC. (d) Correlation analysis between SEC23B and GATA1 gene expression, 
performed in 27 HCs, showed a direct correlation between the two genes (Pearson correlation r 
= 0.742, p = 0.00001). 
 
In this second case, we also suspected an impaired GATA1 expression due to 
the variation c.-71-92G>A in the 5’upstream region of the gene. Accordingly, 
we observed a reduced gene expression in the proband II.2 compared to 
healthy controls, even if not significant (p=0.08) (Figure 4-5b). Since this 
patient was a compound heterozygous for a splice site mutation in SEC23B 
gene, a strong hypo-expression of the gene was observed when compared to 
healthy controls (p=0.002) (Figure 4-5b). WB analyses revealed comparable 
results for both mutations (Figure 4-5c).  
Finally, correlation analysis performed on PBMCs from 27 healthy subjects 
revealed a significant direct correlation between GATA1 and SEC23B 
expression (p=0.00001) (Figure 4-5d). 
 
4.6 Functional characterization of GATA1-G208R mutation 
In order to confirm the ex-vivo data on PBMCs from patient II.3, we 
cloned GATA1 wild type (WT) and G208R mutated sequence in the 
expressing vector pCDNA3.1. Then we transfected both constructs in HEK-
293 cells. We observed a reduced GATA1 gene expression, albeit not 
significant, in cells transfected with pCDNA3.1-GATA1-G208R construct 
when compared to those detected in cells transfected with wild type sequence 
(fold = 0.72, p = 0.08) (Figure 4-6a). Accordingly to previous suggestion, a 
reduced endogenous expression of SEC23B was observed in mutated GATA1 
clone when compared to wild type (fold = 0.66, p = 0.002) (Figure 4-6a). WB 
analyses revealed comparable results for both proteins (Figure 4-6b). 
 
 
Figure 4-6. In vitro characterization of GATA1-G208R mutation. (a) GATA1 and SEC23B 
relative expression of HEK-293 cells overexpressing pCDNA3.1-GATA1 and pCDNA3.1-
GATA1-G208R compared to those transfected with empty vector (E.V.) were shown. GATA1-
G208R construct showed a reduced expression compared to wild type sequence of both genes 
GATA1 (pCDNA3.1-GATA1, 1749833±150723; pCDNA3.1-GATA1-G208R, 
1264421±151656) and SEC23B (pCDNA3.1-GATA1, 1.95±0.03; pCDNA3.1-GATA1-
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G208R, 1.29±0.07). Data are presented as mean ± SE. P value has been calculated by Student t 
test. (b) WB analysis showed a reduced expression of GATA1 and SEC23B in HEK-293 cells 
transfected with pCDNA3.1-GATA1-G208R of comparable extent to that observed by qRT-
PCR. The histograms show the densitometric quantification. Sizes (in kDa) are on the right. 
 
4.7 Characterization of the human promoter region of SEC23B gene 
In order to characterize HuSEC23B promoter we examined 4292 bp 
upstream the ATG of the gene. The evolutionary conservation of this 
nucleotide sequence was analysed by ENCODE web tool: it showed a highly 
conserved region of approximately 500 bp, HuSEC23B/3.29-2.78, which starts 
3300 bp upstream ATG of the gene. This genomic sequence exhibited an 
enrichment of the H3K27Ac histone mark in K562 cell line, suggesting a high 
accessibility of the chromatin to transcription in this locus (Figure 4-7, top). Of 
note, HuSEC23B/3.29-2.78 region is predicted to contain a 720 bp CpG island 
by both in silico tools, CpG Islands Track and EMBOSS Cpgplot. However, 
the analysis of the methylation status of specific CpG dinucleotides in several 
cell types showed that this CpG island is unmethylated in K562 cell line, 
suggesting again an active transcription of this upstream region of HuSEC23B 
gene. Accordingly to in silico data, HuSEC23B/3.44 fragment showed a very 
high luciferase activity compared to pGL3 empty vector (fold = 933.8) in K562 
cells (Figure 4-7, bottom), while HuSEC23B/2.52 exhibited a very low activity 
over empty vector (fold =7.1). Of note, this fragment does not include the 
active transcription region HuSEC23B/3.29-2.78. Although at low levels, the 
smallest fragments (HuSEC23B/0.45, HuSEC23B/0.21) upstream SEC23B 
gene still activated luciferase transcription. As expected, this region is 
predicted by MatInspector to contain the vertebrate TATA motif. Comparable 
results were obtained in HEK-293 cell line (data not shown). 
 
 
Figure 4-7. In silico and functional analyses of HuSEC23B promoter. (a) In silico analysis 
of HuSEC23B upstream region is shown. The H3K27Ac histone mark is the acetylation of 
lysine 27 of the H3 histone protein, and it is thought to enhance transcription. The blue track 
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shows the levels of enrichment of the H3K27Ac histone mark across the genome as determined 
by a ChIP-seq assay in K562 cell line from UCSC Genome Browser (ENCODE web tool). (b) 
A schematic representation of HuSEC23B promoter constructs is shown (on the right). The 
HuSEC23B promoter constructs containing the luciferase reporter gene have been transiently 
transfected into K562 cells. Co-transfection with the Renilla luciferase plasmid (pRL-TK) has 
been performed to normalize transfection efficiency. Luciferase normalized activity for each 
construct is shown on the left. 
 
4.8 GATA1 protein binds to GATA binding sites located in the first intron of 
HuSEC23B 
Ten putative binding sites for GATA1 transcription factor (GATA1bs) 
were predicted by MatInspector web server tool in the promoter sequence of 
SEC23B, in both strands, sense and antisense. Similarly, PROMO predicted the 
presence of 12 GATA1bs in the same genomic sequence. We selected the 
sense binding sites common to both prediction results. The sites which did not 
reflect the consensus sequence W(A/T)GATAR(A/G) were excluded for 
further analyses (Figure 4-8a). We demonstrated the direct binding of GATA1 
to the GATA1bs/HuSEC23B-463 by ChIP assays in both K562 and HEL cells 
at 6 days of erythroid differentiation, while the site GATA1bs/HuSEC23B-
2475 resulted directly bound by GATA1 only in HEL cells at 6 days of 
erythroid differentiation. Of note, the antisense GATA1bs/HuSEC23B-3735 
region is not bound by the transcription factor (Figure 4-8b-c). 
In order to validate the effect of the direct binding of GATA1 on HuSEC23B 
promoter, we co-transfected both GATA1bs/HuSEC23B-2475 and -463 
mutants with GATA1 WT in HEK293 cells. Co-transfection of GATA1 WT 
with GATA1bs/HuSEC23B-2475 and -463 mutants induced a reduction of 30-
40% luciferase activity respectively, compared to HuSEC23B/3.44 WT 
sequence (Figure 4-8d). 
Finally, we analyzed the GATA1-mediated regulation of SEC23B expression 
by co-transfection of several GATA1 mutants (GATA1/G208R, 
GATA1/R216W, GATA1/D218G, and GATA1/V205M) and the 
HuSEC23B/3.44 in HEK-293 cell line. We demonstrated a reduction of 
HuSEC23B/3.44 luciferase activity induced by the mutants G208R (32%) and 
R216W (40%) compared to those observed in co-transfected cells with GATA1 
WT (Figure 4-8e). 
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Figure 4-8. GATA1 directly binds to HuSEC23B promoter. (a) In silico analysis of 
HuSEC23B upstream region showed the presence of putative binding sites of the transcription 
factor GATA1. The binding sites predicted by both in silico tools (MatInspector and PROMO) 
were shown; light gray bar indicate the sense sites predicted by only one tool. (b-c) qRT-PCR 
analysis on GATA1 immunoprecipitated DNA in HEL and K562 cells at 6 days of 
differentiation by hemin. GATA1bs/ETO is the CTR+. HuSEC23B (CTR-) is a sequence 
flanking GATA1bs within HuSEC23B promoter. (d) Luciferase normalized activity of HEK-
293 cells co-transfected with GATA1bs/HuSEC23B-2475 and -463 mutants and GATA1 WT. 
(e) Luciferase normalized activity of HEK-293 cells co-transfected GATA1 mutants 
(GATA1/G208R, GATA1/R216W, GATA1/D218G, and GATA1/V205M) and the 
HuSEC23B/3.44 in HEK-293 cell line. 
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5. Discussion 
 
Mutations in more than 30 genes cause HHA, a highly heterogeneous 
group of rare anemias characterized by complex and often unexplained 
genotype-phenotype correlations. This group of disorders includes conditions 
with very different phenotypes, ranging from (1) hyporegenerative anemias, as 
CDAs to (2) hemolytic anemias due to RBC membrane defects, as HS and 
HST. Although the workflow to diagnose these conditions is a normal clinical 
practice, differential diagnosis, classification, and patient stratification among 
HHA are often very difficult. Indeed, the variety of unspecific and overlapping 
phenotypes often hampers a correct clinical management of the patients. In our 
experience, the clinical and molecular definition of some HHA patients can be 
frequently very hard to obtain. For some conditions, the great phenotypic 
variability is partially explained with the high genetic heterogeneity; this is the 
case of HS, in which five different causative genes have been described 
(Iolascon et al. 2003). However, it is sometimes complicated to distinguish one 
form to the others since the signs can be veiled in symptom-free carriers and in 
mild forms. Moreover, HS can be confused with other clinically-related 
hereditary hemolytic conditions such as CDA II. Indeed, because of hemolytic 
symptoms, frequently CDA II is first misdiagnosed as HS. CDA II patients 
erroneously diagnosed as HS often incur unnecessary interventions, such as 
splenectomy, which leads to a moderate increase in Hb concentration without 
reaching the normal range. The lack of substantial improvement after 
intervention frequently leads to a re-examination of the case, allowing the 
correct diagnosis of CDA II. The most useful indicator to correctly address the 
diagnosis of CDA II is the inadequate reticulocyte count for the degree of 
anemia. Recently, a new clinical index, named bone marrow responsiveness 
index (BMRI) has been created to discriminate a well-compensated hemolytic 
anemia from another characterized by ineffective erythropoiesis. Although this 
index showed a high sensitive parameter (90.4%) to achieve a targeted clinical 
diagnosis of CDA II, it exhibited a low specificity (64.9%) for discriminating 
HS and CDA II patients (Russo et al. 2014). Up to date the cost and time for 
diagnosis of HHA are high. This is largely due to the difficulties in establishing 
the correct diagnosis. This latter is generally based on either biochemical or 
molecular tests that require advanced technical skills that are not available in 
all countries. As a consequence, a long period of time passes before a patient 
can be conclusively diagnosed. This has major psychological impact on the 
patients and their families. Accurate genetic diagnosis of HHA is important not 
only for achieving a definitive diagnosis but also for determining appropriate 
genetic counseling, prognosis and treatment. This is particularly true for 
unspecific symptomatic treatment for hemolytic anemias, as splenectomy, that 
could result not only unuseful, as in CDA II, but also damaging for the 
patients. For example, splenectomy should be banned in DHS for it entails, 
with near certainty, thromboembolic accidents which may be very severe 
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(Stewart et al. 1996). Timely diagnosis could significantly reduce the distress 
for patients and their families, diagnostic costs, and it could have a high socio-
economic impact. Indeed, delayed diagnosis is one of the major denominators 
of life expectancy and secondary effects like multi-organ damage due to iron 
overload, thrombosis or chronic transfusion regimen. 
In the last decade, remarkable progresses have been made in discovering new 
disease genes involved in red blood disorders (Schwarz et al. 2009; Andolfo et 
al. 2012; Andolfo et al. 2013; Babbs et al. 2013; Liljeholm et al. 2013; Andolfo 
et al. 2015; Rapetti-Mauss et al. 2015). This increasing genetic heterogeneity 
underlines the problem of a very complex differential diagnosis (Gambale et al. 
2016). Furthermore, genome sequencing studies suggest that the clinical 
genetic test may be incomplete not only when the causative mutation is 
missing, but also when the genotype/phenotype correlation appears weak. This 
is particularly true when the familial recurrence is unclear, with some relatives 
that only share minor affections. The absence of clear genotype/phenotype 
correlations is often problematic for both genetic counselling and forthcoming 
mutation-specific treatments (Savarese et al. 2014). It is proper in this context 
that the new genomic technologies take place. NGS refers to non-Sanger-based 
high-throughput DNA sequencing technologies. NGS techniques have 
significantly amplified the opportunities of genome analysis. Indeed, this 
technology plays now a major role either in disease gene discovery or in 
clinical use for establishing a genetic diagnosis, with several implications on 
the diagnostic flowchart: the NGS tests could become the first tier test, 
preceding biopsy and other invasive procedures. We can envision a future in 
which the functional integration among the next-generation technologies for 
genomic screening and genomic editing will allow reaching the always pursued 
goal of a targeted diagnosis and therapy (Figure 5-1). 
 
 
Figure 5-1. Integration between technological updates and clinical applications in 
diagnosis and therapy of RBCs diseases. Adult hematopoietic stem progenitor cells (HSPCs) 
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or induced pluripotent stem cells (iPSCs) can be used for gene-therapy approaches. DNA 
extracted from a peripheral blood sample can be used to identify genetic variations by NGS. 
The causative role of these variations can be validate by in vitro/in vivo functional studies and 
then the commonly used CD34
+
 HSPCs may be corrected directly by gene therapy or genome 
editing by CRISPR/CAS9 technology. Alternatively, somatic cells can be isolated by 
fibroblasts of the patient and reprogrammed to pluripotency, with the resulting iPSCs then 
being corrected by gene therapy or genome editing and differentiated through erythroid 
lineage. 
 
In the NGS era, the genetic testing is going to move from few candidate genes 
to wider panels of genes, namely t-NGS approaches. Recent studies have 
already demonstrated the usefulness of t-NGS as a comprehensive and 
invaluable diagnostic tool by means of achieving a correct diagnosis and 
proceeding with careful management of patients (Sikkema-Raddatz et al. 2013; 
Savarese et al. 2014). Indeed, t-NGS resulted to be cost-effective, faster and 
more specific than other NGS technologies, such as WES. Indeed, in WES 
applications typical coverage of exons is approximately 90-95%, with coverage 
much lower in some genes. By contrast, t-NGS can have a much higher or 
often almost complete coverage of all target regions. Of note, in our gene panel 
the predicted coverage has not dropped below 99.3% and the mean sequencing 
coverage of target regions was 99.3%. We used HaloPlex as target enrichment, 
which provides a high specificity and efficiency. Indeed, as described in a 
similar study less than 2% of reads generated by HaloPlex are off-target, in 
comparison with >12% obtained of WES (Savarese et al. 2014). Our data are in 
agreement with these observations. In the pilot study here described we were 
able to confirm the molecular diagnosis in all of the patients previously 
characterized at molecular level. Moreover, by means of pilot design we were 
also able to obtain a molecular characterization in five out seven 
(approximately 72%) HS patients, except for two patients, in which we did not 
find any causative variants. However, we were not able to identify in HHA2 
patient a large deletion in SPTA1 gene, previously detected (Iolascon et al. 
2011). Indeed, large insertions, deletions, and other chromosomal 
abnormalities are often difficult to be identified by NGS approaches. 
One of the most important aspects of the use of t-NGS gene panels in clinical 
practice is their ability to be easily upgradable in view of novel discoveries. 
Thus, after performing pilot study, we designed a broader gene panel, RedPlex, 
composed of 34 RBC-disease genes and assayed 32 HHA patients from 27 
unrelated families. According to the pilot study data, we obtained a conclusive 
diagnosis in approximately 72% of cases. In addition, a lot of patients (39%) 
showed multiple mutations in different loci. The percentage of genetically 
complex patients could be higher, if we consider that many other important 
genes (even if not disease-causing) can also carry damaging alleles. Of note, in 
RedPlex panel we included not only causative genes but also candidate and 
modifier genes (12 out 34). We can easily predict that a broader NGS approach 
could strengthen this observation. For this reason, we have recently 
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implemented RedPlex including additional 37 genes. We are also designing a 
panel of 80-90 modifier genes of HHA. Indeed, monogenic diseases provide 
unique opportunities to understand the real contribution of causative single-
gene mutations and to identify modifiers as they have uniform aetiology, 
detailed phenotyping of affected individuals, and familial clustering (Cutting 
2010). Thus, beyond achieving a definitive diagnosis, knowing the genetic 
basis of these patients can be valuable also for their prognosis. NGS plays a 
pivotal role in this context. The implementation of NGS in clinical practice is 
already a matter of fact. It will result in increased knowledge of genetic and 
genomic differences among individuals that gradually will lead to shift the 
focus from population-based to patient-individualization of the clinical 
management (Iolascon et al. 2015). For the HHA diseases, the role of the 
modifier genes could assume a consistent significance because of the high 
intra-familial and inter-familial-phenotypic differences that may be explained 
with the combinations of multiple disease-causing alleles, or their combination 
with polymorphic variants. 
In our cohort of examined patients, we found at least two interesting 
genetically complex patients. The first, identified as HHA14, was a patient 
with an overlapping phenotype HS/CDA. In this patient, the spherocytic 
component of the phenotype was due to mutations in HS-disease gene SPTA1, 
while the dyserythropoietic component was explainable with the presence of 
additional variants in CDA-related genes, SEC23B and GATA1. Similarly, in 
RED30 patient we observed a complex genotype SEC23B-GATA1 which could 
explain the occurrence CDA II phenotype. Particularly, this patient showed a 
typical clinical and biochemical framework of CDA II; RedPlex analysis 
highlighted the presence of a monoallelic hypomorphic mutation in CDA II-
disease gene SEC23B. Mutations in deep regulatory regions of the SEC23B 
gene as well as digenic inheritance have been hypothesized as additional 
pathogenetic mechanisms of CDA II (Russo et al. 2014). Of note, RED30 
patients showed neither SEC23B regulatory mutations nor large deletions 
within the coding region of the gene. However, a low-expression GATA1 
allele was found in the same patient. So, a digenic inheritance was 
hypothesized in this case. Thus, we further investigated the functional 
relationship between these two genes, demonstrating the direct interaction of 
GATA1 transcription factor on the promoter region of SEC23B. Of note, 
mutations in GATA1 have been already to the CDA variant, XLTDA. GATA1 
gene encodes for the homonymous transcriptional factor. It regulates the 
expression of numerous erythroid-specific genes, such as erythropoietin 
receptor gene (Zon et al. 1991; Chiba et al. 1991), α- and β-globin genes 
(Whitelaw et al. 1990), ALAS2 gene (Surinya et al. 1997; Kaneko et al. 2014) 
and GATA1 gene itself (Kobayashi et al. 2001) during erythroid differentiation. 
Beyond XLTDA, other rare syndromes have been already associated to 
alterations of GATA1 gene expression or protein function. They are: X-linked 
thrombocytopenia, X-linked thrombocytopenia with thalassemia, congenital 
erythropoietic porphyria (CEP), transient myeloproliferative disorder, acute 
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megakaryoblastic leukemia associated with trisomy 21, and anemia associated 
with the production of GATA1s isoform (Ciovacco et al. 2008). GATA1 needs 
two zinc finger domains for normal function. The C-terminal finger is 
necessary for DNA binding, while the N-terminal mediates interaction with its 
cofactor FOG1. In 2000, Nichols described a family with XLTDA due to a 
substitution p.Val205Met (Nichols et al. 2000). It has been demonstrated that 
this highly conserved residue is necessary for interaction of the amino-terminal 
zinc ﬁnger domain of GATA1 with FOG1. This mutation most closely 
resembles those of mice with the knockdown Gata1 mutation. The authors 
showed that the Val205Met mutation abrogates the interaction between 
GATA1 and FOG1, thus inhibiting the ability of GATA1 to rescue erythroid 
differentiation in an erythroid cell line deﬁcient for GATA1. Their ﬁndings 
underscore the importance of FOG1:GATA1 interaction in both 
megakaryocyte and erythroid development and suggest that other X-linked 
anemias or thrombocytopenias may be caused by defects in GATA1 (Nichols 
et al. 2000). In 2005, a novel single base mutation, leading to an amino acid 
substitution (Gly208Arg) within the highly conserved portion of the GATA1 
N-terminal finger domain was described (Del Vecchio et al. 2005). Similarly to 
the previously one described, this mutation leads to a dyserythropoietic anemia 
and macrothrombocytopenia. In our cohort we identified an analogous case 
that has been erroneously diagnosed at first instance as CDA II. By t-NGS 
approach we were able to correctly modify the diagnosis of this patient towards 
a XLTDA; indeed, he showed the same causative mutation p.Gly208Arg 
previously described. 
The study of regulatory network GATA1-mediated on SEC23B gene not only 
provided new insights into the molecular mechanisms of SEC23B regulation, 
but also suggested an explanation of the variability of phenotypes GATA1-
related by means of the crosstalk of this gene with SEC23B. Indeed, we 
demonstrated a specific involvement of two GATA1 mutations in SEC23B 
expression, p.Gly208Arg and p.Arg216Trp, which are the causative variants 
related to XLTDA and CEP, respectively. This observation is also in 
agreement with a CEP case recently reported, in which the severity of the 
anemia has been explained by the co-inheritance of the CEP-related GATA1 
mutation, p.Arg216Trp, with a rare SEC23B missense substitution p.Thr257Ile 
(SNV rs146917730, MAF 0.006) that was predicted damaging (Di Pierro et al. 
2015). Finally, the identification of transcriptional regulatory elements in 
SEC23B promoter could allow the definitive diagnosis of CDAII patients with 
peculiar clinical phenotypes or those with incomplete mutation pattern. 
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6. Conclusions 
 
HHA are chronic disorders with a highly variable clinical picture. Phenotypic 
variety does not only depend on the molecular defect but includes the mode of 
action of specific modifier genes. Knowing these modifier genes and the way 
they contribute to the clinical picture would be a major breakthrough in the 
clinical management of these patients. NGS plays a pivotal role in this context 
and its implementation in clinical practice is already a matter of fact. Indeed, 
NGS studies have identified a greater-than-expected number of genetic 
variations in the human genome. This suggested that existing clinical 
monogenic testing systematically can miss very relevant information, and that 
a lot of genetically complex patients need to be investigated. 
Our analyses demonstrated that RedPlex represents a reliable 
diagnostic/prognostic tool for HHA patients. Indeed, it resulted to be a robust 
platform that overcomes for power, costs, speed, sensitivity and specificity the 
gene-by-gene strategy. Moreover, this approach also allowed the identification 
of “polygenic” conditions, i.e. patients in which the phenotypic variability 
could be explained by the presence of modifier variants associated to causative 
mutations. For the HHA diseases, the role of the modifier genes could assume 
a consistent significance because of the high intra-familial and inter-familial-
phenotypic differences that may be explained with the combinations of 
multiple disease-causing alleles, or their combination with polymorphic 
variants. We investigated the functional interaction between two CDA-related 
genes, GATA1 and SEC23B, thus providing not only new insights into the 
molecular mechanisms of SEC23B regulation, but also an explanation of the 
variability of phenotypes GATA1-related by means of the crosstalk of this 
gene with SEC23B. 
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Diagnosis and management of congenital dyserythropoietic anemias
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ABSTRACT
Congenital dyserythropoietic anemias (CDAs) are inherited disorders hallmarked by chronic
hyporegenerative anemia, relative reticulocytopenia, hemolytic component and iron overload.
They represent a subtype of the inherited bone marrow failure syndromes, characterized by
impaired differentiation and proliferation of the erythroid lineage. Three classical types were
defined by marrow morphology, even if the most recent classification recognized six different
genetic types. The pathomechanisms of CDAs are different, but all seem to involve the regulation
of DNA replication and cell division. CDAs are often misdiagnosed, since either morphological
abnormalities or clinical features can be commonly identified in other clinically-related anemias.
However, differential diagnosis is essential for guiding both follow up and management of the
patients.
ARTICLE HISTORY
Received 20 October 2015
Accepted 10 December 2015
Published online
6 January 2016
KEYWORDS
Inherited anemia; ineffective
erythropoiesis; molecular
genetics; differential
diagnosis; follow up; patient
management
Introduction
The term dyserythropoiesis refers to a condition of
abnormal erythropoiesis affecting the differentiation
and proliferation pathways of the erythroid lineage
with a consequent defective production of red blood
cells (RBCs).[1] Dyserythropoietic anemias can be
divided into primary and secondary forms, and both
inherited and acquired types can occur. Among these
different conditions, the congenital dyserythropoietic
anemias (CDAs) are hereditary diseases that embrace a
highly heterogeneous set of rare or very rare anemias
that result from various kinds of abnormalities during
late stages of erythropoiesis. They are counted as sub-
types of inherited bone marrow failure syndromes
(IBMFS), characterized by morphological abnormalities
of erythroblasts in the bone marrow (BM) and ineffec-
tive erythropoiesis as predominant mechanism of ane-
mia, accompanied by a hemolytic component.[2]
Dyserythropoiesis appears to be a morphological
feature common to several conditions, and this could
account for the difficulties in diagnosis of CDAs.
However, the specific morphological alterations of
the erythroid precursors justify the heterogeneity of
these disorders. Indeed, the three classical types of
CDAs (types I, II and III) are defined on the basis of BM
morphology.[2] Inclusions of additional CDAs, the so-
called CDA variants, despite remarkable morphologi-
cal studies, gradually led to overlapping entities and
imposed a limitation on classification. In spite of
these difficulties, morphological classification is still
widely used in clinical practice. Nevertheless, the
identification of the causative genes of the most
common forms among CDAs in the last two decades
represented an evident advantage for reclassifying
these disorders, as well as in understanding their
pathogenesis. Moreover, uncovering the molecular
basis of CDAs helped to unravel novel aspects of
the molecular biology of erythropoiesis. From the
genetic standpoint, six different types of CDAs are
included in the Online Mendelian Inheritance in Man
(OMIM) compendium of human genes and genetic
phenotypes so far (Table 1). However, this list is
bound to extend. Indeed, as described later in this
review, the discovery of new causative genes is a
continuous evolving process thanks to the develop-
ment of high-throughput technologies, such as next-
generation sequencing (NGS). The identification of
genetic variations underlying hereditary disorders
marked the opening of a new era for genetic and
clinical research. Indeed, beyond, obtaining definitive
diagnosis and planning patient management, knowl-
edge of the genetic basis of these disorders is crucial
in estimating their prevalence and geographical dis-
tribution. According to the estimation by Heimpel
and colleagues in 2010, the prevalence of CDAs varies
widely among European regions, with minimal values
of 0.04 cases/million in North Europe and the highest
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Novel Gardos channel mutations linked to dehydrated
hereditary stomatocytosis (xerocytosis)
Immacolata Andolfo,1,2 Roberta Russo,1,2 Francesco Manna,1,2 Boris E. Shmukler,3,4 Antonella Gambale,1,2
Giuseppina Vitiello,2,5 Gianluca De Rosa,1,2 Carlo Brugnara,6 Seth L. Alper,3 L. Michael Snyder,7,8 and Achille Iolascon1,2*
Dehydrated hereditary stomatocytosis (DHSt) is an autosomal dominant congenital hemolytic anemia with
moderate splenomegaly and often compensated hemolysis. Affected red cells are characterized by a
nonspecific cation leak of the red cell membrane, reflected in elevated sodium content, decreased
potassium content, elevated MCHC and MCV, and decreased osmotic fragility. The majority of symptomatic
DHSt cases reported to date have been associated with gain-of-function mutations in the mechanosensitive
cation channel gene, PIEZO1. A recent study has identified two families with DHSt associated with a single
mutation in the KCNN4 gene encoding the Gardos channel (KCa3.1), the erythroid Ca21-sensitive K1 channel
of intermediate conductance, also expressed in many other cell types. We present here, in the second
report of DHSt associated with KCNN4 mutations, two previously undiagnosed DHSt families. Family NA
exhibited the same de novo missense mutation as that recently described, suggesting a hot spot codon for
DHSt mutations. Family WO carried a novel, inherited missense mutation in the ion transport domain of the
channel. The patients’ mild hemolytic anemia did not improve post-splenectomy, but splenectomy led to no
serious thromboembolic events. We further characterized the expression of KCNN4 in the mutated patients
and during erythroid differentiation of CD341 cells and K562 cells. We also analyzed KCNN4 expression
during mouse embryonic development.
Am. J. Hematol. 90:921–926, 2015. VC 2015 Wiley Periodicals, Inc.
! Introduction
Dehydrated hereditary stomatocytosis (DHSt), also known as hereditary xerocytosis (OMIM 194380), is an autosomal dominant congenital
hemolytic anemia associated with a monovalent cation leak. DHSt consists of a usually compensated hemolysis, associated with moderate spleno-
megaly [1,2]. Blood smears show variable numbers of stomatocytes. The reticulocyte count is elevated, and red cell mean corpuscular volume
(MCV) is increased. DHSt is associated with silent-to-mild hemolysis, pseudohyperkalemia (red cell K1 loss upon storage at room temperature or
in the cold), and perinatal edema [3]. DHSt red blood cells exhibit decreased K1 content and increased Na1 content, usually accompanied by
increased mean corpuscular hemoglobin concentration (MCHC). The cation leak of DHSt red cells resembles that of control RBC in its tempera-
ture dependence, but is of greater magnitude at all temperatures [3]. The definitive diagnosis of DHSt is made by osmotic gradient ektacytometry,
which shows a leftward shift of the bell-shaped curve [4,5]. Occasionally associated hepatosiderosis, beyond that expected from the mild hemolytic
state, suggests a strong tendency to iron overload [6,7]. Unlike hereditary spherocytosis, in which splenectomy can be beneficial, splenectomy in
DHSt is contraindicated due to increased risk of thromboembolic complications [8,9].
The causative gene of the condition was recently identified in the FAM38A gene encoding the mechanosensitive cation channel, PIEZO1
[10,11]. Several functional characterizations of identified PIEZO1 mutations in DHSt families have uniformly demonstrated gain-of-function prop-
erties consistent with the increased net ion fluxes leading to DHSt [7,10–13].
Rapetti-Mauss and colleagues recently identified in two DHSt families a single mutation in the KCNN4 gene encoding the Gardos channel [14].
The Gardos channel/KCNN4 is a widely expressed Ca21-dependent K1 channel of intermediate conductance that mediates the major K1 conduct-
ance of erythrocytes [15]. Inhibition of the Gardos channel in sickle disease patients reduced RBC dehydration and hemolysis, and increased blood
hemoglobin levels [16–19].
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Congenital erythropoietic porphyria linked to GATA1-R216W
mutation: challenges for diagnosis
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Abstract
Congenital erythropoietic porphyria (CEP) is a rare genetic disease that is characterized by a severe
cutaneous photosensitivity causing unrecoverable deformities, chronic hemolytic anemia requiring blood
transfusion program, and by fatal systemic complications. A correct and early diagnosis is required to
develop a management plan that is appropriate to the patient’s needs. Recently only one case of X-linked
CEP had been reported, describing the trans-acting GATA1-R216W mutation. Here, we have characterized
two novel X-linked CEP patients, both with misleading hematological phenotypes that include
dyserythropoietic anemia, thrombocytopenia, and hereditary persistence of fetal hemoglobin. We compare
the previously reported case to ours and propose a diagnostic paradigm for this variant of CEP. Finally, a
correlation between phenotype variability and the presence of modifier mutations in loci related to disease-
causing gene is described.
Key words congenital erythropoietic porphyria; UROS, GATA1, and SEC23B mutations; neonatal hemolytic anemia
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Congenital erythropoietic porphyria (CEP) or Gunther’s dis-
ease is a rare disorder characterized by markedly decreased
uroporphyrinogen III synthase (UROS) activity in erythro-
cytes and signiﬁcantly increased levels of urinary and plas-
matic uroporphyrin I and coproporphyrin I isomers. The
clinical manifestations of CEP are heterogeneous, above all
depending on the amount of residual UROS activity and
ranging from non-immune hydrops fetalis to milder late-onset
forms of dyserythropoiesis (1). Deﬁcit of UROS, the fourth
enzyme in the heme biosynthetic pathway, causes an excess
of uroporphyrin accumulation primarily in bone marrow and
consequently in peripheral blood leading to dyserythropoie-
sis, hemolytic anemia, splenomegaly. The accumulation of
uroporphyrin in other tissues gives rise to skin photosensitivi-
ty, ulcers, erosions, erythrodontia, osteodystrophia, combin-
ing osteolysis and osteoporosis. Secondary infections of
cutaneous lesions may induce to scarring, deformities, and
disﬁgurement of the light-exposed parts of the body such as
hands, ears, nose, and eyelids (2).
The diagnosis is conﬁrmed most commonly by the pres-
ence of biallelic mutations in the UROS gene, inherited in
an autosomal recessive manner, which results in strikingly
deﬁcient activity of the enzyme. To date, 38 mutations have
been identiﬁed in unrelated patients with CEP. The most
common mutation is the missense C73R, occurring in
approximately one-third of the CEP alleles, whereas the
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 491
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Retrospective cohort study of 205 cases with congenital
dyserythropoietic anemia type II: definition of clinical
and molecular spectrum and identification of new
diagnostic scores
Roberta Russo,1,2 Antonella Gambale,1,2 Concetta Langella,1,2 Immacolata Andolfo,1,2 Sule Unal,3 and Achille Iolascon1,2*
Congenital Dyserythropoietic Anemia II (CDA II) is a rare hyporegenerative anemia of variable degree, whose
causative gene is SEC23B. More than 60 causative mutations in 142 independent pedigrees have been
described so far. However, the prevalence of the CDA II is probably underestimated, since its clinical
spectrum was not yet well-defined and thus it is often misdiagnosed with more frequent clinically-related
anemias. This study represents the first meta-analysis on clinical and molecular spectrum of CDA II from the
largest cohort of cases ever described. We characterized 41 new cases and 18 mutations not yet associated
to CDA II, thus expanding the global series to 205 cases (172 unrelated) and the total number of causative
variants to 84. The 68.3% of patients are included in our International Registry of CDA II (Napoli, Italy). A
genotype–phenotype correlation in three genotypic groups of patients was assessed. To quantify the degree
of severity in each patient, a method based on ranking score was performed. We introduced a clinical index
to easily discriminate patients with a well-compensated hemolytic anemia from those with ineffective
erythropoiesis. Finally, the worldwide geographical distribution of SEC23B alleles highlighted the presence of
multiple founder effects in different areas of the world.
Am. J. Hematol. 00:000–000, 2014. VC 2014 Wiley Periodicals, Inc.
! Introduction
Congenital Dyserythropoietic Anemia type II (CDA II) belongs to a subtype of bone marrow failure syndromes characterized by monolineage
involvement and morphological abnormalities in erythroid precursor cells.
Congenital normocytic anemia of variable degree with a reticulocytosis not corresponding to the degree of anemia (ineffective erythropoiesis) is
the main criteria to diagnose CDA II. Because of hemolytic symptoms, it is frequently accompanied with jaundice and splenomegaly [1].
The CDA II BM is hypercellular, due to an exclusive and pronounced increase of erythroblasts, with erythropoietic/granulopoietic ratios of 4.2
(1.7–10.0) (normal reference values 3.6, 1.7–5.4) [2]. Distinct morphological abnormalities of the erythroblasts are observable as a consequence of
the impairment of differentiation and proliferation pathways of the erythroid lineage. Indeed, BM light microscopy reveals more than 10% mature
binucleated erythroblasts, while on electron microscopy vesicles loaded with proteins of endoplasmic reticulum (ER) are found beneath the plasma
membrane [2].
Analysis of red cell membrane proteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE), identifying glycosylation
abnormalities with fast moving band 3 (anion exchanger 1) and band 4.5 (glucose transporter 1), is a highly sensitive and specific diagnostic tool,
even if it is limited by the availability of specialized laboratories.
CDA II belongs to COPII-related human genetic disorders, since it is due to mutations in SEC23B gene (chr 20p11.23) [3,4], which encodes the
cytoplasmic coat protein (COP)II component SEC23B, involved in the secretory pathway of eukaryotic cells. This multisubunit complex mediates
accumulation of secretory cargo, deformation of the membrane and anterograde transport of correctly folded cargo for budding from the ER
towards the Golgi apparatus [5].
The clinical and biochemical suspect of CDA II is confirmed most commonly by the presence of biallelic mutations in the SEC23B gene, inher-
ited in an autosomal recessive manner. The prevalence of CDA II in Europe shows substantial variations between different countries [6], but it
exhibited the highest value in Italy, where a founder effect has been demonstrated [7]. To date, 66 different mutations in 142 unrelated cases have
been reported [8–17].
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Successful hematopoietic stem cell
transplantation in a patient with congenital
dyserythropoietic anemia type II
Unal S, Russo R, Gumruk F, Kuskonmaz B, Cetin M, Sayli T, Tavil B,
Langella C, Iolascon A, Cetinkaya DU. Successful hematopoietic stem
cell transplantation in a patient with congenital dyserythropoietic
anemia type II.
Abstract: CDA are a group of inherited, rare diseases that are
characterized by dyserythropoiesis and ineﬀective erythropoiesis
associated with transfusion dependency in approximately 10% of cases.
For these latter patients, the only curative treatment is HSCT. There
are very limited data on HSCT experience in this rare disease. Herein,
we report a five-yr six-month-old girl with compound heterozygous
mutations in SEC23B gene, who was diagnosed to have CDA type II
and underwent successful HSCT from her matched sibling donor.
Sule Unal1, Roberta Russo2,3, Fatma
Gumruk1, Baris Kuskonmaz1, Mualla
Cetin1, Tulin Sayli4, Betul Tavil1,
Concetta Langella2,3, Achille Iolascon2,3
and Duygu Uckan Cetinkaya1
1Division of Pediatric Hematology, Hacettepe
University, Ankara, Turkey, 2Department of
Molecular Medicine and Medical Biotechnologies,
University Federico II, Naples, Italy, 3CEINGE
Advanced Biotechnologies, Naples, Italy, 4Ankara
Pediatric Hematology and Oncology Research
Hospital, Ankara, Turkey
Key words: transplantation – congenital
dyserythropoietic anemias – iron – SEC23B
Sule Unal, Division of Pediatric Hematology,
Hacettepe University, Ankara 06100, Turkey
Tel.: +90 312 305 1170
Fax: +90 312 311 2398
E-mail: suleunal@hacettepe.edu.tr
Accepted for publication 24 February 2014
CDA are a group of rare heterogenous disorders
characterized by dyserythropoiesis, ineﬀective
erythropoiesis, iron overload, and specific light
and electron microscopy findings of nucleated
erythroid precursors (1–3). Patients usually pres-
ent with anemia, jaundice, splenomegaly, low
reticulocyte count despite erythroid hyperactivity
(3). There are broadly three main types of CDA
(CDA I, II, and III), due to mutations in
CDAN1, SEC23B, and KIF23, respectively (3–7).
However, there are additional CDA variants that
do not fit to any three classical types, such as
CDA patients with KLF1 and GATA1 muta-
tions. To date, 157 cases from 137 diﬀerent CDA
II families with SEC23B mutations were molecu-
larly analyzed (3, 8). Type II patients are charac-
terized by erythroid hyperactivity in bone
marrow with no megaloblastic changes, in addi-
tion to high numbers of binucleated normoblasts
with occasional multinucleated erythroid precur-
sors (1). The nucleated erythroid precursors of
patients with CDA type II may exhibit double
membrane appearance under electron micros-
copy (9). There are patients with CDA who have
mild-to-moderate anemia who require no regular
transfusions. On the other hand, treatment alter-
natives include erythrocyte transfusions for
patients with severe anemia, iron chelation to
decrease complications related to transfusional
iron overload, interferon alpha for some of type
I and splenectomy for some of the type II
patients (10, 11). However, the only curative
treatment for patients with CDA is HSCT (12,
13). There is scarce data in the reported literature
on the use of HSCT as a therapeutic and curative
option in patients with CDA (2, 12, 14–17).
Herein, we report a five-yr six-month-old girl
with CDA II who had compound heterozygous
mutations in SEC23B gene and was successfully
transplanted from a matched sibling donor.
Abbreviations: ATG, antithymocyte globulin; CDA, con-
genital dyserythropoietic anemias; CMV, cytomegalovirus;
CyA, cyclosporin A; gDNA, genomic DNA; GVHD,
graft-versus-host disease; HSCT, hematopoietic stem cell
transplantation; LDH, lactate dehydrogenase; MCV, mean
corpuscular volume; RDW, red cell distribution width;
VOD, veno-occlusive disease.
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Regular Article
RED CELLS, IRON, AND ERYTHROPOIESIS
Multiple clinical forms of dehydrated hereditary stomatocytosis arise
from mutations in PIEZO1
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Key Points
• Dehydrated hereditary
stomatocytosis is
characterized by abnormal
RBC morphology but may
involve pseudohyperkalemia
and perinatal edema.
• This syndrome is associated
with germline mutations in
PIEZO1, encoding a
transmembrane protein that
induces mechanosensitive
currents.
Autosomal dominant dehydrated hereditary stomatocytosis (DHSt) usually presents
as a compensated hemolytic anemia with macrocytosis and abnormally shaped
red blood cells (RBCs). DHSt is part of a pleiotropic syndrome that may also exhibit
pseudohyperkalemia and perinatal edema. We identified PIEZO1 as the disease gene
for pleiotropic DHSt in a large kindred by exome sequencing analysis within the
previously mapped 16q23-q24 interval. In 26 affected individuals among 7 multigen-
erational DHSt families with the pleiotropic syndrome, 11 heterozygous PIEZO1
missense mutations cosegregated with disease. PIEZO1 is expressed in the plasma
membranes of RBCs and its messenger RNA, and protein levels increase during in
vitro erythroid differentiation of CD341 cells. PIEZO1 is also expressed in liver and
bone marrow during human and mouse development. We suggest for the first time
a correlation between a PIEZO1mutation and perinatal edema. DHSt patient red cells
with the R2456H mutation exhibit increased ion-channel activity. Functional studies
of PIEZO1 mutant R2488Q expressed in Xenopus oocytes demonstrated changes in
ion-channel activity consistent with the altered cation content of DHSt patient red
cells. Our findings provide direct evidence that R2456H and R2488Q mutations
in PIEZO1 alter mechanosensitive channel regulation, leading to increased cation transport in erythroid cells. (Blood. 2013;
121(19):3925-3935)
Introduction
Dehydrated hereditary stomatocytosis (DHSt), also known as he-
reditary xerocytosis (Online Mendelian Inheritance in Man [OMIM]
194380), is an autosomal dominant congenital hemolytic anemia
associated with a monovalent cation leak. DHSt consists of a usually
compensated hemolysis, associated with moderate splenomegaly.1,2
Blood smears show variable numbers of stomatocytes, sometimes
rare and ill-formed, and likely to be overlooked. The reticulocyte
count is elevated, and red cell mean corpuscular volume (MCV) is
slightly increased. DHSt red blood cells (RBCs) exhibit decreased
intraerythrocytic K1 content and increased intraerythrocytic Na1
content, usually accompanied by increased mean corpuscolar hemo-
globin (Hb) concentration. The cation leak of DHSt red cells
resembles that of control RBCs in its temperature dependence,
but is of greater magnitude at all temperatures.3 The deﬁnitive
diagnosis of DHSt is ascertained by osmotic gradient ektacytometry,
which shows a leftward shift of the bell-shaped curve.4,5 Occasion-
ally, associated hepatosiderosis beyond that expected from the mild
hemolytic state suggests a strong tendency to iron overload.6
Unlike hereditary spherocytosis, in which splenectomy can be
beneﬁcial, splenectomy in DHSt is contraindicated due to increased
risk of thromboembolic complications.7,8
DHSt can present as an isolated erythroid phenotype or as
associated with pseudohyperkalemia, with pre- and/or perinatal
edema, or with both pseudohyperkalemia and effusions. The pre- and/or
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Congenital dyserythropoietic anemia type II, a recessive disorder of erythroid differentiation, is due to muta-
tions in SEC23B, a component of the core trafﬁcking machinery COPII. In no case homozygosity or compound
heterozygosity for nonsense mutation(s) was found. This study represents the ﬁrst description of molecular
mechanisms underlying SEC23B hypomorphic genotypes by the analysis of ﬁve novel mutations. Our ﬁndings
suggest that reduction of SEC23B gene expression is not associated with CDA II severe clinical presentation; con-
versely, the combination of a hypomorphic allele with one functionally altered results in more severe phenotypes.
We propose a mechanism of compensation SEC23A-mediated which justiﬁes these observations.
© 2013 Elsevier Inc. All rights reserved.
Introduction
Congenital dyserythropoietic anemia type II (CDA II, OMIM 224100)
is a genetic hyporegenerative anemia characterized by ineffective
erythropoiesis and distinctmorphological abnormalities of the erythro-
blasts in the bone marrow (BM). Anemia of variable degree, jaundice
and splenomegaly are common clinical ﬁndings [1]. This condition
belongs to COPII-related human genetic disorders [2]. It is due tomuta-
tions in SEC23B (chr 20p11.23), a component of COPII complex, the core
trafﬁcking machinery of the endoplasmic reticulum-Golgi [3]. Approxi-
mately 60 different causative mutations have been described, localized
along the entire coding sequence of the gene [1,4–6]. Themost frequent
are nucleotide substitutions (75% missense/nonsense), whereas frame-
shift and splicingmutationswere observed in 15% and 10% respectively.
The vast majority of patients have two mutations (in the homozygous
or compound heterozygous state), according to the pattern of autoso-
mal recessive inheritance. In no case homozygosity or compound het-
erozygosity for two nonsense mutations was found, a situation likely
to be lethal. However, few cases with two hypomorphic mutations
have been described so far [4,5].
Here we characterize three novel CDA II cases, two of them with
fully hypomorphic genotype. We demonstrated a compensatory mech-
anism SEC23A-mediated of SEC23B hypo-expressed alleles.
Material and methods
Patients and mutational screening
Diagnosis of CDA II was based on history, clinical ﬁndings, laboratory
data, morphological analysis of aspirated bone marrow and whenever
possible on evidence of hypoglycosylated band 3 by SDS-PAGE. Samples
were obtained after informed consent for the studies, according to the
Declaration of Helsinki. Whenever possible, relativeswere investigated.
Genomic DNA and mutational screening were performed as previously
described [4].
In silico and ex vivo analyses on mRNA
Prediction analyses for splice sitemutationswere performed byweb
server tools, splice site prediction by neural network (http://www.
fruitﬂy.org/seq_tools/splice.html) and human splicing ﬁnder (http://
www.umd.be/HSF/) (Table 2).
RNA isolation from peripheral blood mononuclear cells (PBMCs),
cDNA preparation and quantitative real-time (qRT)-PCRwere performed
as described [7]. Relative gene expression was calculated by using the
2−ΔCt method, while the mean fold change=2−(average ΔΔCt) was
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Missense mutations in the ABCB6 transporter cause dominant
familial pseudohyperkalemia
Immacolata Andolfo,1,2 Seth L. Alper,3,4,5 Jean Delaunay,6 Carla Auriemma,1,2 Roberta Russo,1,2
Roberta Asci,1 Maria Rosaria Esposito,1 Alok K. Sharma,3 Boris E. Shmukler,3,4,5 Carlo Brugnara,7
Lucia De Franceschi,8 and Achille Iolascon1,2*
Familial Pseudohyperkalemia (FP) is a dominant red cell trait characterized by increased serum [K1] in
whole blood stored at or below room temperature, without additional hematological abnormalities. Func-
tional gene mapping and sequencing analysis of the candidate genes within the 2q35–q36 critical interval
identified—in 20 affected individuals among three multigenerational FP families—two novel heterozygous
missense mutations in the ABCB6 gene that cosegregated with disease phenotype. The two genomic sub-
stitutions altered two adjacent nucleotides within codon 375 of ABCB6, a porphyrin transporter that, in
erythrocyte membranes, bears the Langereis blood group antigen system. The ABCB6 R375Q mutation did
not alter the levels of mRNA or protein, or protein localization in mature erythrocytes or erythroid precursor
cells, but it is predicted to modestly alter protein structure. ABCB6 mRNA and protein levels increase dur-
ing in vitro erythroid differentiation of CD341 erythroid precursors and the erythroleukemia cell lines HEL
and K562. These data suggest that the two missense mutations in residue 375 of the ABCB6 polypeptide
found in affected individuals of families with chromosome 2-linked FP could contribute to the red cell K1
leak characteristic of this condition. Am. J. Hematol. 00:000–000, 2012. VC 2012 Wiley Periodicals, Inc.
Introduction
Familial pseudohyperkalemia (FP) is a dominant red cell
trait characterized by increased serum [K1] measured in
whole-blood specimens stored at or below room tempera-
ture. This dominantly inherited trait is not accompanied by
clinical symptoms or biological signs except for borderline
abnormalities of red cell shape [1]. FP Lille was described
in a large family of Flemish origin with morphologically nor-
mal red cells [2,3]. In this family, cation leak measured in
vitro in the presence of ouabain and bumetanide showed
normal K1 efflux at 378C, which increased greatly at 22
and 98C [3]. The subsequently reported asymptomatic
cases of FP Chiswick and FP Falkirk [4] were remarkable
for increased MCV. FP Lille was mapped to 2q35–q36 by
genome-wide search [5].
FP is considered as a subtype of the larger group of
leaky red blood cell (RBC) disorders that include Southeast
Asian ovalocytosis [6], dehydrated hereditary stomatocyto-
sis (DHSt) [7], overhydrated hereditary stomatocytosis
(OHSt) without or with neurological symptoms [8], and
cryohydrocytosis (CHC). There appears to be a continuum
between FP and DHSt that may be associated with
pseudohyperkalemia [7]. Several temperature-dependent
patterns of cation leak have been characterized in these
conditions by measurements of 86Rb influx insensitive to
ouabain and bumetanide [9]. FP stands out among the
leaky RBC disorders for its mild clinical and hematological
phenotype and its minimal changes in cell shape.
Mutations in several genes have been shown to cause
red cell cation leak disorders. These include SLC4A1 (an
ion exchange) in CHC and in atypical forms of hereditary
spherostomatocytosis [10,11], RHAG (Rh-associated gly-
coprotein) in isolated stomatin-deficient OHSt [12,13]
GLUT1 (glucose transporter 1) in echinocytosis with par-
oxysmal dyskinesia [14], stomatin-deficient cryohydrocyto-
sis [15] or in CHC [16] or pseudohyperkalemia and hemo-
lysis [17] with neurological symptoms, and PIEZO1
(mechanosensitive cation channel protein FAM38A) in
DHSt [18]. These findings suggest that distinct missense
mutations in various red cell membrane solute transporters
or channels generate cation leak pathways either through
the mutant proteins themselves or by deregulating one or
more independent cation permeabilities of the red cell
membrane.
Here, we report that in FP Lille, linked to chromosome
2q, and in two other FP families, the causal mutations
reside in the same codon (375) of the ABCB6 gene, encod-
ing the ABCB6 polypeptide reported to be a porphyrin
transporter [19]. This protein was recently identified in the
RBC membrane [20], where it displays the Langereis blood
group [21].
Materials and Methods
Cases reports. FP Lille was first diagnosed in a mother and
daughter [2,3] from a large family of Flemish descent. The carriers
were hematologically normal. Temperature-dependent 86Rb influx
showed a shallow slope pattern [5]. The responsible gene was mapped
to 2q35–q36 (very close to marker D2S1338), based on the analysis of
23 carriers (including the above-mentioned daughter as individual II.8)
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